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Abstract

MARKERLESS LUNG TUMOR TRAJECTORY ESTIMATION FROM ROTATING CONE
BEAM COMPUTED TOMOGRAPHY PROJECTIONS
By Shufei Chen
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016.
Major Director: Geoffrey Hugo, Ph.D.
Associate Professor and Director, Medical Physics Graduate Program
Department of Radiation Oncology
Respiration introduces large tumor motion in the thoracic region which influences
treatment outcome for lung cancer patients. Tumor motion management techniques require
characterization of temporal tumor motions because tumor motion varies patient to patient, day
to day and cycle to cycle. This work develops a markerless algorithm to estimate 3 dimensional
(3D) lung-tumor trajectories on free breathing cone beam computed tomography (CBCT)
projections, which are 2 dimensional (2D) sequential images rotating about an axis and are used
to reconstruct 3D CBCT images.
A gold standard tumor trajectory is required to guide the algorithm development and
estimate the tumor detection accuracy for markerless tracking algorithms. However, a sufficient
strategy to validate markerless tracking algorithms is lacking. A validation framework is
developed based on fiducial markers. Markers are segmented and marker trajectories are
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obtained. The displacement of the tumor to the marker is calculated and added to the segmented
marker trajectory to generate reference tumor trajectory. Markerless tumor trajectory estimation
(MLTM) algorithm is developed and improved to acquire tumor trajectory with clinical
acceptable accuracy for locally advanced lung tumors. The development is separate into two
parts. The first part considers none tumor deformation. It investigates shape and appearance of
the template, moreover, a constraint method is introduced to narrow down the template matching
searching region for more precise matching results. The second part is to accommodate tumor
deformation near the end of the treatment. The accuracy of MLTM is calculated and compared
against 4D CBCT, which is the current standard of care.
In summary, a validation framework based on fiducial markers is successfully built.
MLTM is successfully developed with or without the consideration of tumor deformation with
promising accuracy. MLTM outperforms 4D CBCT in temporal tumor trajectory estimation.

1. Introduction

1.1. Radiation Therapy for Lung Cancer
Lung cancer is the most commonly diagnosed and most lethal cancer worldwide.1 In 2008
for instance, 1.61 million new cases of lung cancer were diagnosed, accounting for 12.7% of the
total cancer incidences and meanwhile, 1.38 million deaths were caused by lung cancer,
accounting for 18.2% of the total cancer deaths of the year. The survival of lung cancer patients
is among the poorest of all cancer types. The overall five-year survival rate (typically used as the
measurement of survival) regardless of treatment type is 15% for lung cancer patients in United
States.2 Surgical resection is the primary treatment choice for lung cancer patients with earlystage diseases, but the majority patients (about 80%) are medically inoperable. Radiotherapy
(RT) is the primary treatment modality for inoperable patients, but the prognosis is poor. The 5year survival rate of lung cancer patients who underwent RT-only treatment is about 5%-40%
depending on the tumor stage 2,3. Techniques to improve the RT treatment outcome of lung
cancer are highly desired.
The goal of RT is to deliver a high enough radiation dose to kill the tumor cells while
minimizing the dose to the normal tissue. To ensure targeting, radiographic imaging, normally a
computed tomography (CT) image, is taken to model a patient’s anatomy, including tumor and
surrounding tissues at the simulation stage. Tumors are identified and delineated by physicians
on planning CT images. Figure 1 shows an example of delineated tumor in CT images in a lung
cancer case. A treatment plan is created based on the planning CT to meet the RT goal. Before
1

treatment, the patient should be setup as close to the planned position as possible. After setup,
radiation beams are delivered according to the plan. RT is normally prescribed with multifractional doses meaning that a treatment course may last up to several weeks. The time lag
between the simulation and delivery cause patient geometry variation in relation to the planned
geometry (simulation stage) due to the existence of geometric uncertainties, especially for later
fractions.

Figure 1. An example of tumor delineation in CT images for a lung cancer
patient.

Geometric uncertainties are studied carefully for the purpose of precise targeting. Major
sources of geometric uncertainties are the delineation uncertainty of the gross tumor volume
(GTV) or other critical structures (e.g. organ-at-risk (OAR)), setup error, uncertain microscopic
extension of tumor and organ motion 4. In the delineation process, the limits in image quality of
2

imaging modalities (e.g. partial volume effect5), as well as inter-and intra-observer uncertainties
impact the delineation accuracy and consistency. Delineating on multi-modality images with
clear guidelines could help to improve the delineation uncertainty. Setup error is defined as the
position difference between the positions of selected anatomical landmarks at the time of
treatment in relation to their positions at planning 6. Image guided radiotherapy (IGRT) and
immobilization techniques help improve the setup accuracy, which is about 2-4 mm in the
thoracic region7-10. To address Microscopic extension of tumor beyond that visualized on the
imaging modalities, a margin added to the GTV to create a clinical target volume (CTV) 11,12.
Another major source of geometrical uncertainty is organ motion. Organ motion is defined as
the organ position change with respect to the bony anatomy. Interfractional organ motion such
as the baseline variation in the location of the respiratory trajectory relative to the bony anatomy
is similar in magnitude to bony setup errors and is managed by IGRT13-15. Intrafractionally,
respiration is an important factor that influences the improvement of treatment outcome in lung
cancer because respiration introduces large intrafractional tumor motion during the treatment.
Tumor motion at the thoracic region may be greater than 2cm when the tumor is close to the
diaphragm16-18, substantially larger than other regions.
To account for geometric uncertainties, traditionally a safety margin based on the population
statistics is added to the target to create planning target volume (PTV) to ensure target dose
coverage as recommended by International Commission on Radiation Units and Measurements
Reports (ICRU 50 and ICRU 62) 6,19. The margin added should be large enough to maintain
tumor coverage in the target region, while at the same time it should be as small as possible to
spare normal tissue. The GTV to PTV margin is larger for lung cancer compared to some other
3

cancers because of the respiration-induced tumor motion, leading to a larger dose to normal
tissue.
To safely spare (reduce dose to) the normal tissue without compromising dose coverage to
the tumor is critical to improve treatment outcomes for lung cancer. Normal tissue dose is
proportional to the prescription dose and irradiated volume. The irradiated volume of healthy
tissue increases when the CTV to PTV margin increases. Hence, margin reduction is beneficial
in two ways. On one hand, margin reduction reduces the dose to the normal tissue if prescribing
the same dose to the target as in larger PTV margin plans. Reducing the prescription dose is
normally not chosen as a way to spare the normal tissue, because the dose coverage of the target
will not be enough to kill tumor cells. On the other hand, margin reduction enables safe dose
escalation. Dose escalation has been reported to show improved local tumor control with less
local failure and increased survival 20-25. However, dose escalation also increases the risk (dose)
to the OAR (e.g. lung, heart, esophagus, and etc.). A safe dose escalation prescribes higher dose
to the treatment target while respecting the dose tolerance to the normal tissue. With a smaller
margin (irradiated volume), the target can be prescribed with higher dose under the same dose
tolerance of the normal tissue as larger margin plans. The increased dose effect to the OAR due
to dose escalation is reduced by dose reduction from margin reduction. In sum, reduction of
geometric uncertainties and the associated safety margin is crucial at achieving the RT goals,
either improving treatment outcome or reducing normal tissue toxicity. Therefore, as an
important component of geometric uncertainties in lung cancer, organ motion should be
monitored and studied carefully.

4

Techniques to manage motion during treatment incorporate the tumor motion in the treatment
planning or the treatment delivery. Treatment techniques such as breath-hold, respiratory gating,
tumor tracking have been developed to manage the respiration-induce motion during RT
treatment delivery.26-30 Breath-hold techniques intend to deliver radiation beams to patients only
during the breath-hold intervals. Patients hold their breath voluntarily or through active
breathing control (ABC) during the treatment. The whole treatment requires several breathholds. The treatment efficiency (time cost) depends on the patient’s ability to hold their breath.
Similar to breath-hold, respiratory gating involves periodically turning radiation on normally at
the end-of-exhale phase (EOE) of a patient’s breathing cycle. Reducing the beam-on intervals in
breathing cycles improves the motion management. But patients are held on the treatment couch
longer, causing more discomfort for sick patients and degraded treatment efficiency. Tumor
tracking techniques propose to track the tumor movement with the radiation beam, requiring
real-time knowledge of tumor locations and prediction accounting for system latency. However,
limited knowledge of the real time tumor location is the major complexity preventing the routine
implementation of tumor tracking clinically.

Figure 2 Two examples of breathing curves from RPM system for lung cancer patients. The left curve is more regular
and periodic; the right curve is more irregular and aperiodic.

5

Incorporating temporal variations in patient specific geometric into the treatment planning
process is an alternative approach to manage motion31-39. Probabilistic treatment planning is able
to reduce the safety margin by generating a patient-specific field margin, which is modeled from
patient-specific variations (mainly respiratory organ motion) in the repetitive imaging during
treatment.34 Four-dimensional (4D) inverse planning includes the temporal variation in the
planning dose evaluation. The hypothesis is that the repetitive breathing motion is treated as
random motion. The probability distribution function (PDF) of patient-specific respiratory
motion is convolved to blur the dose distribution with respiration to approximate the dose
distribution taking account full 4D anatomy in the respiration cycle36-39. Incorporating
variability models into the treatment planning whether through adaptation or 4D inverse planning
requires patient-specific characterization of the tumor motion. In sum, all these motion
management treatment techniques require monitoring the tumor motion during simulation for
treatment planning and during the treatment delivery for verification of the breathing pattern.
The following section will discuss techniques to estimate tumor motion during planning.
1.2. Characterization of Respiratory Motion for Treatment Planning
Current techniques that are used to monitor the tumor trajectory can be grouped into 4
categories: external surrogates, implanted internal fiducial markers, internal anatomical
surrogates and direct tumor estimation. The first three categories track the tumor motion
indirectly through surrogates. And the last category directly estimates tumor motion from the
tumor information. The following will discuss these 4 categories of motion characterization
techniques.

6

1.2.1. External Surrogates
Signals from external surrogates such as tidal volume measured by spirometer28,40 and
abdominal skin surface displacement from external markers41-43 are used to measure respiratory
motion. A spirometer measures patient respiratory volume of air inhaled and exhaled by the
patient through a mouthpiece with an electronic pneumotachometer. One common system
measuring the abdominal surface displacement signal is the RPM system. The RPM system
captures the anterioposterior motion of a block attached to the patient’s abdomen through an
infrared camera. The captured signal from the camera is imported to the linked computer and
processed. A correlation model (normally linear) is applied to the external signal to estimate the
internal target motion and position. The model relies on the assumption that the tumor position
is consistently correspondent with the external surrogate signal. Several studies have been
conducted to assess the correlation between the internal tumor motion and the surrogate signals
(denotes as the internal/external correlation).44-51 The internal/external correlation coefficient is
high assuming linear correlation and the internal signal correlates slightly higher to spirometer
signal than to the abdominal displacement signal45-47,49 But the correlation is not temporally
invariant, rather changes intra- and interfractionally. The correlation between tumor motion and
external marker position is poor under breath-hold conditions50. Many studies observed time,
phase shift, as well as amplitude mismatch between the tumor motion and abdominal
displacement.44,46,49,51 The internal/external correlation is sensitive to direction.47,48 The best
correlation is between the superoinferior (SI) tumor position and skin marker motion, but at the
AP direction, the correlation is poor. The internal/external correlation varies with different
tumor locations, skin marker locations as well as patient breathing patterns.44,47,48 The
7

internal/external correlation coefficient changes day to day.46,52 The external surrogates offer no
indication of the interfractional baseline(location of the respiratory trajectory relative to the bony
anatomy) variation 14,15,34 leading to different internal/external correlation at different days.
The respiratory tumor motion tracking using these external surrogates requires no
acquisition of X-ray imaging allowing continuous tracking throughout imaging or treatment
delivery. But due to the inconsistency of the inner/external correlation, external surrogate alone
is an inaccurate indicator of tumor position and motion.
1.2.2. Internal Implanted Markers
Since external markers fail to correctly represent tumor motion, markers are implanted
inside or near the tumor of the patient to represent tumor motion/position. The implantation of
markers is through percutaneous needle insertion or bronchoscopy. Markers serve as reliable
surrogate to locate or track tumors53,54. One type of marker is electromagnetic markers and the
positions of markers are detected using a magnetic source and receiver coil array55,56. The other
is radiopaque fiducial markers (normally gold markers) is detected from segmentation on planar
X-ray images most commonly fluoroscopy53,54,57-61.
The concern of tumor tracking through implanted markers affecting both
electromagnetic and radiopaque fiducial markers is the limits and risks of marker implantation.
Studies showed that marker implantation through percutaneous needle insertion introduces a risk
of pneumothorax up to 45%62-68, so performing implantation through needle insertion is not
widely accepted by clinicians. Inserting markers via bronchoscopy is feasible and safe limited to
peripheral-type lung tumors but not the central lung tumors.59,61 The marker implantation may
not be acceptable to patients especially those who might be expecting a ‘non-invasive’ treatment
8

modality with RT. Another concern that limits marker implantation is the marker migration67-69 ,
which leads to misrepresentation of the tumor position.
For tumor tracking with radiopaque fiducial makers, the additional dose to patient due to
planar X-ray imaging is another concern. In order to reduce the frequency of X-ray imaging and
thus the dose to patients, researchers introduce techniques which combine the external surrogate
and internal fiducial together to model and predict the tumor position.42,70,71 A linear model is
built at the simulation to derive fiducial marker positions from signal of external surrogates.
During the treatment stage, fiducial marker positions are used to update the model at certain time
intervals. Updating the model with internal fiducial marker positions can overcome or moderate
variations of internal/external correlation which tracking with external surrogate encounters.
Since X-ray images are only acquired when updating the model, the imaging frequency and the
patient dose is reduced.
1.2.3. Internal Anatomical Surrogates
Due to the risks and limits of tracking tumor with implanted fiducial markers, researchers
have increased their interest in obtaining respiratory signal from the internal anatomical features
on X-ray images. Diaphragm72,73, carina74,75 and other anatomical features76 are analyzed in
fluoroscopic images as internal anatomical surrogates for the estimation of the tumor motion.
Studies have shown that diaphragm and carina are well correlated to tumor motion according to
studies. A model obtained from the training data is applied to the trajectory of the anatomical to
estimate the tumor trajectory. These surrogate anatomical structures are easy to detect in x-ray
images. However, when these features are far apart from the tumor, one may need to enlarge the
field of view (FOV) to include them in the images resulting in extra radiation dose to the patient.
9

Furthermore, the baseline shift of the tumor is difficult to be estimated by the feature surrogate
modeling.
1.2.4. Direct Tumor Estimation
The limitations or risks of tumor trajectory tracking using external surrogates, implanted
marker surrogates as well as internal anatomical surrogates, leads to the research interest in
direct the tumor trajectory estimation from the tumor mass. This category is separated into 2
groups. One group is 4D tomography such as four-dimensional computed tomography (4DCT).
The other group estimates instantaneous tumor positions in sequential 2D image datasets and the
proposed method in this dissertation belongs to this group.
4D Tomography
In the thoracic region, respiratory correlated imaging acquisition techniques, such as
4DCT77-79, 4D cone beam computed tomography (CBCT)80,81 are performed to reduce the
uncertainties and artifacts induced by the respiration-induced organ motion. A 4D scan consists
of a set of three dimensional (3D) images reconstructed from two dimensional (2D) images at
multiple phases (normally 10 phases) of the respiratory cycle. 2D images are sorted into
different phases by analyzing a respiratory trace, which is simultaneously obtained as the 2D
images by external surrogates. The determination of phase is based on either the amplitude or
the phase angle. Phase angle is defined as the fraction of time between user-specified phases of
breathing. For example, if end-of-inhale is phase 0% of the breathing cycle, end-of-exhale is
around 50% to 60%. Tumor is delineated on each 3D phase images and one mean tumor
position is obtained for each phase. The trajectory of the tumor motion is formed by these phase
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mean tumor positions. Thus, the tumor motion extracted from 4D tomography is an average of
all respiratory cycles.
The major disadvantage of 4D tomography is that the output is a single tumor position for
each phase of 3D image. However, the tumor motion is not simply periodic but it suffers from
cycle to cycle variation and shift of the mean or exhale tumor position (drift)13,17,82 as shown in
Figure 2. Output cycle from 4D tomography cannot provide accurate information to estimate
cycle-to-cycle variations and drift. Hence, instantaneous tumor trajectory needs to be estimated
in order to accurately measure these variations.
Direct Instantaneous Tumor Estimation
To directly investigate the instantaneous tumor positions, the intensity of the tumor mass is
analyzed by tracking83-85 and gating86-88 in fluoroscopic images. Support Vector Machine
(SVM)-based87, template-based83 and optical flow-based84 algorithms are implemented to obtain
the tumor positions directly from the X-ray images. Fluoroscopy provides two dimensional (2D)
images of the patient, and thus dual fluoroscopy is required in order to obtain 3D tumor
trajectory. However, the dual fluoroscopy imaging causes double dose to the patient and most
clinics do not have the modality available. Hence, researchers have investigated tracking in
single-imager mounted to the treatment gantry, e.g. linac-integrated cone beam computed
tomography (CBCT), which provides rotational images (projections) of the patient enabling the
reconstruction of the 3D trajectory. CBCT is widely used in IGRT to assist patient setup, plan
evaluation, and adaptive therapy. Many clinics have already installed CBCT in their treatment
rooms. Using the projections from the CBCT acquisition already taken in the patient setup to
obtain tumor trajectory requires no extra dose to the patient.
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One method utilizing the CBCT projections to obtain tumor trajectory information is to
reconstruct the 3D anatomy at each time point when a projection is acquired, a method termed
‘projection to volume’89-93. The method proposes a 4DCT reconstruction technique by
deforming a prior source CT to match the measured projections. The technique works well
under simulated conditions, but for actual CBCT data from free-breathing patients, the
implementation of the 4D deformation model will be much more complicated. Estimation tumor
trajectory in CBCT projections is simpler and potentially easier for clinical implementation than
the project to volume techniques.
Some studies implement techniques such as Amsterdam Shroud (AS) 81,94 and principal
component analysis (PCA)95 to extract breathing signal from the CBCT projections. AS
technique acquires 1D breathing signals extracted from AS images where the SI motion is
enhanced. A derivative image is created from the original projection image by computing the
derivative along the SI direction. The derivative image is averaged horizontally resulting a 1D
column bar for each projection and the 1D bars of all the projections are posted together to from
the AS image. Breathing signals are calculated from the pixel shifts by aligning 1D column bars
one by one. The technique works only well when there are distinct structures in the FOV (e.g.
diaphragm), but there is no guarantee such structures in the view. The other idea of breathing
signal extraction is to separate the breathing motion induced intensity changes from the gantry
rotation induced changes. PCA technique can be used to separate different motion modes by
selecting different principal component eigenvectors. The PCA analysis performed on projection
images is more useful at determining breathing phase other than extracting full tumor motion
trajectory. Yan et al. implement the PCA on AS image as a more reliable technique compared to
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AS95 alone. The downsides of these techniques are that the breathing signals are 1D (SI
direction) and more importantly, the signals do not directly indicate the actual movement of the
tumor.
The proposed method template matching-based markerless tumor tracking (MLTM)
estimates the full tumor trajectory which includes not only the breathing amplitudes but also the
tumor locations. Studies96-98 have evaluated small, parenchymal lesions such as those amenable
to stereotactic body radiotherapy. Solid validation is only available in phantom cases. For the
clinical patient cases, some studies rely on physician delineation at the projections as a ground
truth96, which is limited to comparisons in small datasets by the time-consuming nature of the
segmentation. Other studies compare the result of the markerless tracking algorithm to an
average target trajectory from 4D CBCT97,98, which does not allow for evaluation of the quality
of the tracking on short time scales. Some studies97,99 implemented a background subtraction
step in projections before template matching. The idea is to subtract the digital reconstructed
radiograph (DRR) generated from tumor-free 4DCT, where tumor was removed, from the
projection image. I first proposed applying this technique in lung cancer patients in my AAPM
presentation in 2010100. The subtraction technique enhances the tumor contrast. However,
concerns include whether the enhanced tumor is the real tumor, for example whether the removal
of tumor in either FBCT or CBCT to generate subtraction DRR creates an artificial boundary
that could drive the template to an erroneous match.
1.3. Thesis Objective and Outlines
In this work, I extend the template matching-based tumor tracking on CBCT projections to
larger lung cancer lesions (late-stage disease) infiltrating the chest wall, hilum, or mediastinum.
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The treatment for larger lesions is more challenging because the large volume limits the dose that
could be prescribed to the target within the respect of the normal tissue tolerance. The treatment
outcome for late-stage disease is worse than early stages and thus treatment techniques for
improving the treatment outcome are highly desired. Better understanding the tumor motion of
larger lesions could result in smaller safety margins added to the target so that dose escalation
could be applied to have better local control. However, larger lesions are more challenging cases
to apply template matching-based tumor trajectory estimation. First, the treatment course lasts
much longer for larger lesions (may be up to 7 weeks) than those amenable for SBRT (around a
week), so the study of breathing pattern change throughout the treatment is more crucial for
larger lesions. Tumor volume change as well as shape change in respect to the planning tumor
due to the treatment response should also be taken into account in the template matching process.
The other reason is that the soft tissue boundary may not be as clear as those well-defined small
parenchymal tumors. Therefore, in this thesis, a markerless tumor trajectory estimation
technique is developed for locally advanced tumors.
The primary goal of this thesis is the development and evaluation of a template-matching
based markerless tumor trajectory estimation algorithm (MLTM) with clinically-acceptable
accuracy (about 3mm) for lung tumor localization in CBCT projection images. MLTM will be
compared against the clinical standard which is the 4D CBCT to see whether the technique can
improve the tumor localization. Four specific aims are introduced to achieve this goal.
(1) The first aim is to develop and evaluate a validation framework to assess MLTM because
a reliable validation method is lacking for direct tumor tracking. A validation method based on
markers is built from marker segmentation on projection images. Tumor-to-marker displacement
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is used to transform the marker trajectory to the tumor trajectory as the reference. Different
approaches to calculate tumor-to-marker displacement is evaluated and an appropriate approach
is selected to build the validation framework.
(2) The second aim of the thesis is to achieve clinical acceptable accuracy for MLTM with
minimal tumor shape and volume change. How to create templates that are best suitable for
template matching on projections is an important issue to solve. Template matching on rotating
gantry images is challenging. The template matching may not get the true matching for some
gantry angles. In this case, a prediction method is needed to guide the matching process. The
expected outcome of this goal is an appropriate approach of template and a prediction method
that could guide the template-matching.
(3) Patients studied here undergo multi-fractional RT which takes up to 7 weeks to complete
the treatment. For later fractions, tumor shape and volume changes are no longer negligible.
Therefore, the third aim of the thesis is to adapt the MLTM algorithm account for tumor shape
and volume changes with adequate accuracy. Affine transformation and B-spline deformable
registration is performed to the planning fan beam CT (FBCT) to transform the planning tumor
to the daily tumor. The results of these two registrations are compared to the original method.
An approach of registration with the best results is selected.
(4) The clinical standard of tumor trajectory estimation method is 4D CBCT. This work
claims to outperform 4D CBCT and a study should be conducted to support this statement. Thus,
the fourth aim of the thesis is to analyze the accuracy of the MLTM algorithms and compare it
against 4D CBCT.
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The outline of the thesis is described as follows. The validation framework and its accuracy
estimation are covered in Appendix I and Chapter 2. The development of MLTM despite of
tumor shape and volume change is taken place in Appendix II and Chapter 3 and with the
existence of significant tumor shape and volume change in Chapter 4. The tumor trajectories
obtained from MLTM are compared against clinical standard (4D CBCT) in Chapter 5. Finally
in Chapter 6, results of previous chapters are discussed and concluded, and the further direction
is suggested.
Appendix I and Appendix II are manuscripts reporting on the first two specific aims in this
work. Subsequence chapters supplement the appendices with further details and discussions on
the project development and analysis. It is intended that each appendix to be read prior to its
corresponding chapter.
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2. Validation Framework

2.1. Introduction
A gold standard tumor trajectory is required to guide the algorithm development and estimate
the tumor detection accuracy for the MLTM algorithm. However, a sufficient strategy to
validate markerless tracking algorithms is lacking. Instead, some validation studies96 rely on
manual segmentation of the target in the projections themselves as a reference, which is limited
to comparisons in small datasets by the time-consuming nature of the segmentation. Because a
CBCT scan contains about 600 projections (free breathing CBCT) up to 2400 projections (4D
CBCT), it’s impractical to manually delineate all the projection images. Other studies compare
the results of the markerless tracking algorithm to an average target trajectory from 4D
CBCT97,98, which eliminates the time dependent motion pattern variation such as baseline drift
and cycle to cycle variation not allowing for evaluation of the quality of the tracking on short
time scales. Approaches such as external surrogates and internal anatomical surrogates are not
considered due to the deficiency stated in section 1.2.1and 1.2.2. In this work, implanted fiducial
markers are used to generate reference tumor trajectory because implanted markers can serve as
reliable surrogates for tumor motion detection.
It is suggested to read Appendix I first, then proceed to read the remainder of this chapter. A
validation framework to generate a gold standard tumor trajectory from implanted fiducial
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markers is introduced in Appendix I. And the current chapter emphasizes on the rationale of the
framework formation.
2.2. Patient Database
Table 1. Patient and marker characteristic.

Patient

Stage

Location

GTV
(cm3)

Markers
Implanted

Markers
Detected

1

T4N3M0

RUL

88.9

2

2

2

T4N2M0

Right Hilum

30.3

3

4

3

T4N2M0

Right Hilum/RLL

58.3

3

2

4

T3N1M0

LLL

42.7

2

1

5

T3N2M0

Right Hilum

144.2

3

5

6

T2N3M0

Left Hilum

46.2

2

1

As in Table 1, 5 patients with either a stage IIIA or IIIB pathologically-confirmed non-smallcell lung cancer (NSCLC) are studied in this dissertation. All the research work in this thesis is
performed on these 5 patients. Patients were implanted with fiducial gold markers (Visicoil,
RadioMed Corporation, Tyngsboro, MA).

2 to 3 fiducial markers were implanted via

bronchoscopy in tumor or lymph node regions for each patient. The numbers of markers
implanted and visible are summarized in Table 1. The discrepancy of the marker implanted and
marker detected in the projections may due to marker breakage and marker migration. All
patients were treated with 3D conformal RT (62.6-70 Gy) with standard fractionation (1.8-2 Gy,
five days per week). A respiration-correlated 4D FBCT (Brilliance Big Bore, Philips Medical
Systems, Andover, MA) is obtained as the planning CT for each patient before treatment. Slow
gantry 4D CBCT were obtained at each treatment fraction of the treatment, denoted as daily
CBCT, via a commercially available on board imaging device (Varian Medical Systems, Palo
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Alto, CA) for each patient. The scan conditions were 125 kVp, 20 mA and 20 ms per projection
with half-fan geometry. There are about 2400 projections in each 4D CBCT scan and they
covered all 360 degrees of gantry rotation. Fiducial markers and primary tumor were contoured
for all 10 phases of all 4D FBCT, and weekly (about 7 CBCT scans per patient) for 4D CBCT.
Those weekly delineated 4D CBCT are denoted as weekly CBCT in the following chapters.
2.3. Background on 3D Medical Image registration
Currently, multiple radiological images are generally used to guide diagnosis and treatment
in healthcare. A technique to accurately relate information in different images is required to
fully exploit the image information for physicians and researchers. Image registration is the
solution, which determines the spatial correspondence between two images of a scene. In the
process, points from one image could find the corresponding points in the other image. The
outcomes of registration include fusion information, transformation, change detection and object
recognition.
Image registration provides a means to accurately relate information in different images,
most widely used to align tomographic images in 3D space, e.g. aligning FBCT and CBCT. The
most often used registration techniques assume a ‘rigid body’ meaning that the structure of
interest deforms and distorts negligibly. This type of techniques is called rigid image registration.
In reality, organs do deform substantially in images due to organ motion, treatment response and
different imaging modalities. Non-rigid registration techniques that can compensate tissue
deformation are of high requirement. The outcome of image registration is a major part of the
research method in this thesis. In the rest of this chapter specifically, image registration is used

19

to obtain target positions without delineation, and the transformation is also employed to
transform a structure of interest to match the target structure in Chapters 3 and 4.
2.3.1. Rigid Image Registration
The definition of rigid is that the distances between all points of the target image remain
constant compared to the source image. The rigid transformation is 6 degrees of freedom for 3D
images, including translation, rotation and reflection. Rotation is rotating an object about a fixed
point without changing its size or shape; translation is moving an object in space without
changing its shape, size or orientation; reflection is flipping an object across a line without
changing its shape or size. Assuming a point f in the source image and the transformed
position is f ' , the function to conduct the transformation is shown below:
f '  R  f  c  Τ  c

(1)

where the matrix R is a rotation matrix, c is the center of rotation (usually the center of the
image), and matrix T is translation matrix. The rotation matrix is parameterized by the Euler
angles (one in 2D, three in 3D).
Rigid image registration can be accomplished automatically and manually. Automatic
rigid image registration is used in routine clinical practice. The registration of the source and
target images is obtained by iteration and comparison of various possible matches of the two
images. The process is formulated as an optimization problem by a ranking function based on
some physical considerations (correlation, mutual information and etc.). Manual rigid
registration is also in popular use to compare images and it is employed in the following study of
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this chapter. This process manually rotates and moves the source image around the target image
and obtains the registration by comparing the critical features in the fusion images.
2.3.2. Affine Transformation
Affine transformation includes dilation, which expands and contracts an object without
changing shape or orientation. An affine transformation is a transformation which preserves
straight lines and ratios of distances between points on any straight line. Scaling, translation,
rotation, reflection, shear, similarity transformations, spiral similarities as well as any
combination and sequence of above are all affine transformations. The affine transformation
adds scaling and shearing to the rigid transformation matrix leading to 12 degrees of freedom in
the registration parameters for 3D images. The function of affine transform is shown below:
f '  A  f  c  Τ  c

(2)

where other variables are defined the same as in equation (1) except the matrix A has no
restrictions compare to matrix R meaning that the image can be translated, rotated, scaled, and
sheared. Affine transformation does not increase the applicability of image registration
dramatically relative to rigid body transformation, as tissues deform in more complicated ways.
Therefore, affine transformation is not incorporated into the study of this chapter, but will be
used in Chapter 4.
2.3.3. Deformable Image Registration
Deformable image registration (DIR) is more complicated compared to rigid registration
and it models individual voxel dependent distortion, which can be made using either finite element model101,102, B-splines103,104, thin-plate splines105,106, optical flow algorithms107, or fluid
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flow algorithms108. The process of DIR requires 4 components: an interpolator to sample the
voxels, a transformation to specify how a volume can change during the various steps in the
optimization, a similarity metric (such as mutual information, cross correlation, and etc.) to
measure the score for optimization, and an optimizer to find the best possible solution. The
optimizer compares the scores given by the similarity metric for the evaluated transformed
spaces and obtains the best solution by marching over a subset of solution space.
The DIR components chosen in this dissertation are B-Spline interpolator, B-Spline
transformation, mutual information, and gradient decent optimizer. The software used to perform
DIR is Elastix109,110. B-spline DIR can represent smooth and continuous motion which is
anatomically realistic and it is computationally efficient because changes to one region do not
affect the remainder of the transform since B-splines only have local support. B-spline is short
for “basis spline”. A function is represented as a linear combination of basis functions.
v  x    pi i

 x

(3)

Where  i is a piecewise cubic polynomial, pi is a scaling factor. Noting Fi is the fixing image
intensity at voxel i , and M i is the moving image intensity. In the registration process, mutual
information (MI) was calculated and used to optimize the B-spline coefficients. The registration
contains a global transformation and a local transformation. The global transformation describes
the overall motion of an object which can be estimated simply by rigid registration. The local
transformation defines the deformation of the object. The idea of the transformation is to deform
the object by manipulating an underlying mesh of control points. The control points are defined
on the fixed image and they are normally on a regular grid. The transformation of a point can be
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computed from only a few surrounding control points and it benefits the modelling of the local
transformation and enables fast computation.
In this work, the average CT of the free breathing planning CT and average CBCT are
registered and the resulting transformation is used to transform the phase images. The image
quality of the CBCT phase images is poor and hence the average CBCT is used to obtain better
registration results. The patient image data are stored in Pinnacle format and needed to
transform to MetaImage ( *.mhd ) as the input of Elastix. The spacing of the grid for defining
control points is 8.0, 4.0, 2.0, and 1.0 voxels. The DIR is running at multi-resolution with downsampling and the resolution pyramid is 8.0, 4.0, 2.0, and 1.0 voxels.
2.4. Validation Framework Formation
2.4.1. Framework Outline
The marker-based validation framework setup in Appendix I is summarized as following.
For each scan of CBCT projections, markers are segmented in projections p  (1, 2,3

N ) using a

MATLAB GUI developed by collaborators111 , where N is the number of projections of the scan.
The resulting marker trajectory is denoted as M  {m1 , m2 , m3 ,

mN } , where m p is the marker

position vector at left-right (LR), anterior-posterior (AP), and superior-inferior (SI) directions.
Markers are implanted inside the tumor, but the marker centroid does not necessarily represent
the tumor centroid and an offset often exists. Tumor-to-marker displacement (TMD) is added to

m p for the generation of the reference tumor trace R  {t1 , t 2 , t 3 ,

t N } where vector t p is the

tumor position vector. TMD can be computed from the mean tumor positons minus the mean
marker position of the marker trace segmented in the CBCT projection images. The mean tumor
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positions can be obtained either from contours on the reconstructed CBCT or image registration
of an image with known tumor positions to the CBCT.
The relationship over the treatment course between marker and tumor is not well known
and TMD is considered as the factor to represent the relationship in this work. One strong factor
influences TMD is marker migration. In a treatment, normally about 3 markers are implanted to
each patient and the distances between the markers are checked to detect possible migration112.
Significant marker migration (e.g. migrating into the pleural space) normally happens within 6
days after the insertion of the marker 67. Marker positions are stable for 2–4 weeks from the
beginning of radiotherapy112. With the exception of migration, TMD changes slowly,
continuously due to the slow, continuous change in tumor volume and shape during therapy.
Thus, a linear relationship should reasonably model for the marker and tumor relationship as
shown in Figure 1 of Appendix I. A linear model for each patient is obtained through linear
regression which minimizes the sum of squared residuals and leads to a close expression for the
estimated value δ of TMD.
δ = α  βd

(4)

where d is the scan day of the CBCT relative to the planning CT which is day 1, α and β are
variables computed from the minimization of the sum of squared residuals. This estimated value
δ is used to obtain non-delineated scans. However, due to tumor motion and deformation,

marker position may not be reliable after 1 month112. For example, Patient 6 demonstrates a nonlinear relationship in TMD at the last measurement after 1 month of treatment, as shown in
Figure 1(f) of Appendix I. In this case, marker migrates and TMD should be calculated directly
other than through equation (1).
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2.4.2. TMD Approaches
For the calculation of TMD, besides physician delineated tumor contours, tumor centroid
positions can be obtained from image registration with aligned critical structures. Different
approaches are compared to decide which approach is compatible with delineated contours. As
mentioned in Section 2.2, only weekly CBCT scans were delineated by physicians in our datset,
so TMD for each approach is calculated and compared against contour based method on weekly
CBCT scans. TMD calculated from delineated tumor contours is denoted as TMD_c. In image
registration approaches, the tumor positions of the daily CBCT are obtained by transforming the
known tumor positions from a delineated scan (either planning CT or CBCT).
Three image registration approaches were compared to TMD_c. The first approach is to
manually align tumors (rigid registration) of the planning FBCT and the daily CBCT in the
treatment planning system (Pinnacle), and the calculated TMD is denoted as TMD_rigid_tumor.
The differences between the TMD_rigid_tumor and TMD_c are calculated for each weekly
CBCT and the root mean square errors (RMSE) are listed in Table 2. There are large
discrepancies between the TMD_rigid_tumor and TMD_c due to registration errors caused by
tumor regression, which is up to 60% volume reduction throughout the treatment course.
The other attempt is to rigidly register the nearest delineated CBCT to the daily
unsegmented CBCT automatically by aligning tumors, and the resulting TMD is TMD_CBCT.
The rationale behind this is to accommodate tumor deformation in the registration without the
employment of deformable registration. The calculation is done on weekly delineated CBCT
scans, and the transformed tumor position is also compared against the delineated tumor position
in Table 3. The errors are significantly reduced compared to TMD_rigid_tumor. The last
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attempt is to register the planning CT and the daily CBCT to the tumor through deformable
image registration (DIR), resulting TMD_DIR. The errors of TMD_DIR as shown in Table 4
and they are similar to TMD_CBCT, slightly better. However, the errors of both attempts are
still larger than the errors (1.2/1.6/2.6 mm at LR/AP/SI directions from Appendix I) of expected
TMD, δ , estimated from the linear model built on TMD_c. The advantage of TMD_DIR is that
it does not require physician delineation and could be automatic.
Table 2. RMSE of TMD_rigid_tumor.

Patient
1
2
3
4
5
6
Mean

LR/mm
2.0
1.0
5.1
4.1
4.5
10.0
5.3

AP/mm
1.3
0.7
2.0
2.3
6.1
4.8
3.5

SI/mm
2.0
2.5
6.0
2.7
4.4
5.7
4.2

AP/mm
0.6
1.9
0.4
0.3
2.0
4.5
2.2

SI/mm
1.2
2.3
1.8
1.9
2.1
4.9
2.6

AP/mm
1.9
1.3
2.8
0.8
2.1
2.4
2.0

SI/mm
2.1
0.8
1.7
0.6
2.1
3.8
2.1

Table 3. RMSE of TMD_CBCT.

Patient
1
2
3
4
5
6
Mean

LR/mm
1.2
2.0
3.0
2.0
1.1
4.0
2.4

Table 4. RMSE of TMD_DIR.

Patient
1
2
3
4
5
6
Mean

LR/mm
0.8
1.1
2.4
1.7
2.7
3.3
2.2
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2.4.3. Intrafractional Consideration of TMD
TMD is not constant during breathing, and the difference between TMD at different
breathing phases calculated from TMD_c is up to 5 mm with a standard deviation of 1.5 mm.
However in this work, the marker trace was not corrected phase to phase. A mean TMD is
computed for each CBCT scan and used as the correction factor to generate reference tumor
trajectory from markers instead of phase to phase calculation of TMD. There are two reasons
behind this. First of all, the goal of the validation framework is for application to both normal
CBCT scans and 4D CBCT scans. Phase-to-phase computation of TMD is not available on the
normal CBCT scans. Secondly, the delineation uncertainty is highly involved in the calculation
of phase TMD. The image quality of the phase-specific image in the 4D CBCT is poor
compared with the average image, leading to larger delineation uncertainty of the targets. Figure
3 shows two examples of the average cycles of tumor positions (TC) obtained from the first two
delineated weekly 4D CBCT. Average cycles of marker trajectory (MS) generated from the
direct marker segmentation in the projection images are also plotted as references. Even though
the amplitude of tumor movement and marker movement may not be the same, they should have
the same moving pattern, in other words when the amplitude of the marker movement increases,
the amplitude of tumor movement should increase respectively. For patient 3, the amplitude of
tumor movement increases as does the marker amplitude in the plots. However, in week 2 of
patient 2, the amplitude of marker motion deceases compared to week 1 but the amplitude of
tumor motion increases. Furthermore, the shape of the average cycle of tumor positions,
especially TC2 for both patients, is not as expected to be a smooth curve. This is mainly due to
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delineation uncertainties caused by poor image quality of CBCT phase image and observer
uncertainties. The phase TMD obtained from the phase contours are not necessarily more
accurate than a single TMD from the average position, therefore the average TMD is used as the
correction factor for the whole CBCT scan in this work.

Figure 3. Tumor and marker trajectories for the first two weekly CBCT of Patient 2 and 3 at the SI direction. MS1 and
TC1 are the marker and tumor trajectories respectively for week one, MS2 and TC2 for week two.

2.5. Conclusion
In the remaining of this thesis, TMD is computed from TMD_DIR for the framework
formation. The validation framework is demonstrated to be an accurate approach to generate
reference tumor trajectory for MLTM with an accuracy of 2.2/2.0/2.6 mm at LR/AP/SI directions.
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3. MLTM in the Context of Minimal Target Deformation

3.1. Introduction
The validation framework set up in Chapter 2 is used to guide the development of MLTM.
The next major aim of this dissertation is to implement and improve MLTM for tumors with
minimal shape or volume change. The more difficult task of adapting MLTM accounting for
shape and volume change is deferred to the following chapter. Appendix II describes the major
analyses and conclusions. The current chapter provides the supplementary information in the
development of the algorithm design. The major contributions of this chapter are to extend an
existing MLTM in the following ways. Firstly, projection images are preprocessed to obtain
higher quality projections. The main goal is to improve soft tissue contrast (the tumor visibility).
Secondly, a study is conducted to investigate the shape and the appearance of the tumor
template, which is the key component in the template matching process. The creation of tumor
templates may introduce artifacts or artificial boundaries that could cause errors in the template
matching process. In the following, more results, which lead to the selection of the template
type, will be discussed. Finally, a prediction method is introduced to constrain the searching
region for template matching in order to obtain more precise matching results. The advantages
and limitations of this method will be discussed.
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3.2.

(a)

The Principles of MLTM
3.2.1. Overview of Template

Matching
Template matching113,114 is a
technique used to classify objects in an
image by matching a set of templates to the
(b)

image. If an image contains an unknown
object, a set of templates with known
objects are matching to the image to find
out the best match which determines what
the object is. Template matching is also
position sensitive, meaning that it can also
be used to register images. In this chapter,
template matching is implemented to
estimate the position of an object in an
image.

In order to identify an object A in a
Figure 4. An example of template and search image.

search image S( x, y ) as listed in Figure 4
(b), where ( x, y ) represent the horizontal and vertical coordinates of each pixel, a template
image T(u, v) of the object shown in Figure 4 (a), where (u, v) represent the horizontal and
vertical coordinates of each pixel in the template image, is made from a part of the search image
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or a different image which contains the shape and intensity information of the object. When
conducting template matching, the template T(u, v) moves over the whole search image and the
similarity score at each pixel position ( x, y ) of the search image is calculated. The position with
the highest score is considered as the best match. One commonly used similarity measure is the
sum of squared differences (SSD) of the intensity between the two images. The intensity of
pixel ( x, y ) in the search image is defined as I s ( x, y ) and the intensity of pixel (u, v) in the
template image as I t (u, v) . The SSD is calculated at each pixel ( x, y ) in the search image as
listed below:
Tcols Trows

SSD( x, y )     I s ( x  i, y  j )  I t (i, j ) 

2

(5)

i 0 j 0

where Trows and Tcols denote the number of rows and columns of the template images. This
method to compute the similarity is computationally expensive, so more efficient ways to
compute the coefficients are needed. The calculation in Equation (5) can be expanded as
Tcols Trows

SSD( x, y )    I s ( x  i, y  j ) 2  I t (i, j ) 2  2 I s ( x  i, y  j ) I t (i, j )

(6)

i 0 j 0

Tcols Trows

where the terms

  I ( x  i, y  j )
i 0 j 0

s

2

 I t (i, j ) 2 could be considered to be constant across all

possible matches (i,j) and the remaining term 2 I s ( x  i, y  j ) I t (i, j ) is depends on the 2D shift
(I,j). Hence, cross correlation coefficient (CC) defined in the following equation is utilized to
simplify the calculation of SSD. The expression of CC is similar to convolution as shown below:
Tcols Trows

CC( x, y )    I s ( x  i, y  j ) I t (i, j )
i 0 j 0
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(7)

Thus, convolution, which is calculated by Fast Fourier Transform (FFT), was implemented in the
computation of CC to improve computation efficiency. Given Fs as the FFT of I s , Ft as the FFT
of I t , and IFFT () as the Inverse Fast Fourier Transform function, the correlation matching
surface is:
  IFFT ( Fs Gt* )

(8)

In practice, the normalized version of the cross correlation, noted as normalized cross correlation
(NCC) is used to eliminate effects caused by different illumination situations of the images.
Tcols Trows

NCC( x, y ) 

  ( I ( x  i, y  j )  I )( I (i, j )  I )
i 0 j 0

s

s

t

t

(9)

Tcols Trows

  ( I ( x  i, y  j )  I ) ( I (i, j )  I )
2

i 0 j 0

s

s

t

2

t

where I s and I t are the mean intensity of the search image and the template image respectively.
NCC is not robust if there are occlusions in the search image, which are extraneous features and
overlying tissues (bones, tables, and etc.). To overcome this deficiency, a more robust approach
noted as Orientation Correlation (OC)115 was implemented in this thesis. OC is the CC
calculated on orientation images (orientation of intensity gradient) instead of the original
intensity images. The orientation image f of an image with intensity I is calculated by:
 I ( x, y )
I ( x, y ) 
f ( x, y )  sgn 
i

y 
 x

0

where i is the complex imaginary unit and sgn( x)   x
x
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(10)

if x  0
otherwise

f s and f t are calculated for intensity images of the search image I s and the template I t

correspondingly. And the OC of the template and the search image is the CC of f s and f t .
Orientation correlation matches the orientation of the gradient for each pixel and thus it is
insensitive to high density noise and occlusions. This advantage is important for this work
because the target images, CBCT projections, have high noise levels and the matching of tumor
are influenced by occlusions such as bones, treatment table, cables and etc.
3.2.2. Workflow of MLTM Tumor Detection
Template matching has been employed to extract tumor trajectories or breathing signals
in fluoroscopic images of RT83,86,116,117. Reference templates which correspond to different
breathing phases and tumor positions are generated from either 4DCT or fluoroscopy images
taken at the simulation stage (refer to Appendix II for more detail). The tumor position or the
breathing phase of a search image is obtained by matching the template to the search image. The
full tumor trajectory or breathing signal is generated by running the template matching at a set of
sequential images of a time period.
In this thesis, the author implements template matching in tumor trajectory estimation at
CBCT projections instead of fluoroscopic images. The latter are acquired at a fixed gantry angle,
usually the AP view, in fluoroscopy, while the CBCT projections are rotated over 360 degrees or
200 degrees. The rotational geometry of CBCT makes it more challenging to implement the
technique. First of all, more templates need to be generated to cover the different geometry due
to gantry rotation. Secondly, contrast and motion enhancement techniques cannot be applied the
structure of interest due to the changing geometry for the rotating images. Furthermore, the
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variations in tumor visibility at different gantry angles also complicate the template matching.
The purpose of this work is to achieve clinically-acceptable tracking accuracy of lung cancers
using template matching-based algorithm in CBCT projections.
The basic framework of MLTM was developed previously by Hugo et al. for small, welldefine and radiosurgery eligible tumors 98. Briefly, the procedure consists of five steps as shown
in Figure 5: 1) Gross tumor volume (GTV) (in green) was delineated at each phase of the
planning 4DCT by physicians and it was expanded with a margin to obtain the expanded GTV
(Ex-GTV, in purple). Note that the Ex-GTV was not equivalent to the clinical target volume used
to plan for microscopic disease, but instead was used exclusively for template generation. 2) A
masked CT was generated by zero padding regions outside the Ex-GTV of each phase of the 4D
scan, and the masked CT was shifted to the daily tumor position by registering the planning CT
and the daily free breathing reconstructed CBCT to the tumor. 3) The shifted masked CT was
forward projected onto the virtual detector plane to generate digitally-reconstructed radiographs
(DRR) at all breathing phases and at periodically-spaced gantry angles, which are termed the
tumor templates (TT). 4) The TT was cropped and 2D/2D registration of TT to the measured
projection (MP) was performed by template matching (TM) within a search region. The 2D
tumor position in each MP of the free breathing CBCT was calculated by matching the MP with
its corresponding TT. The 2D registration searched in a window of ±4 mm around the 2D tumor
position at the detector plane (equivalent to ±2.7 mm at the room coordinate system) to find the
best match of the TT and the MP. The red contour in Figure 1 showed a matching result. 5) The
2D tumor positions are reconstructed to the 3D tumor trajectory by backprojection. The masked
CT was shifted to the daily tumor position in step 2) because the difference between the real
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daily tumor position and the tumor position of the masked CT should be small enough in order to
obtain correct tumor template in step 3) and use small template searching windows in step 4).
The angle between an object and the radiation source as well as the length of tissue travelled by
radiation beams are different if the position of the object is different. The shape and the intensity
of the tumor in the template are related to the radiated angle and the beam travel length. If the
tumor position the masked CT is far away from the real daily tumor position, the shape and
intensity of the tumor template would be incorrect. The masked CT is shifted to be closer to the
real daily tumor position to obtain more accurate tumor template. Furthermore, if the tumor
position in the tumor template is closer to the daily tumor position, the searching window in step
4) could be smaller so that the matching results are more refined and the computation is faster.
The following simple enhancements were added to this basic framework, but are not the
main focus of the aim:
1) Histogram equalization is applied to the search region in the projection images to
improve the contrast.
2) The search window for template matching is adapted to ±22.5 mm, which is ±15 mm
in the room coordinates, instead of the ±4 mm window to account for the up to 3 cm
tumor motion.
3) The similarity metric used to conduct template matching is changed from block NCC
to orientation correlation.
4) A spatial probabilistic method developed by Poulsen et al 118 is used to reconstruct
3D tumor positions from 2D tumor positions than using simple backprojection
technique in the original framework.
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The main adaptions will be introduced in the following sections.
GTV & Ex-GTV

Ex-GTV Masked CT

TT

Cropped TT Cropped MP

2D Trajectory

Figure 5. Workflow of MLTM in CBCT projections.
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TM Result

3D Trajectory

3.3. Software Development
The central code of the MLTM is a MATLAB-based code, denoted as Tumor Detect, which
outputs the tumor 3d positions of CBCT projection images. The inputs of the algorithm are a set
of templates, tumor position in each template, gantry angle and phase of each projection. The
previous method for generating these inputs was mainly based on using the treatment planning
system Pinnacle, which has many manual steps and was time-consuming. Automatic method
needs to be developed in order to improve the efficiency and reduce manual errors. An in-house
data read/write and automated data processing computing framework called RCF library is
available to serve these purpose at generation of inputs for the Tumor Detect code.
TT is generated from each phase of the tumor-only CT by forward projection using an
already-existing in house GPU-based algorithm called ‘project’. The project code simulates the
generation of a projection image. The pixel intensity in a simulated projection represents the
integration of the attenuation along the ray path. The simulated projections can be generated at
any gantry angle. The isocenter of the rotation is an input parameter which is specified by the
user. For the same structure with different positions relative to rotation isocenter of the project
code, the projections of the structure in the projection image are different due to divergence. In
order to make the TT image as similar to the measured projection, the tumor position relative to
the isocenter of the rotation in the masked CT should be roughly the same as the tumor position
relative to the isocenter in the measured CBCT. So the isocenter of rotation for the project code
should be at the isocenter of the reconstructed CBCT when the planning CT and reconstructed
CBCT are registered to the tumor as shown below:
ISOcor  ISOCBCT  T

37

(11)

where T is the translation from registering the planning CT to the CBCT (using a region of
interest containing only the tumor), ISOcor is the center of rotation of the project code and
ISOCBCT is the isocenter of the CBCT. The tumor centroid position in the Tumor Template with

this setting of rotation isocenter is at the tumor position of the daily CBCT, which means that the
searching window of the 2D image registration from the Tumor Template to the projections can
be constrained to a small region.

Figure 6 Flow Chart of generation of the input data for Tumor Detect algorithm. The red boxes are the input data
for the Tumor Detect algorithm.

The required input data of the Tumor Detect algorithm are Tumor Templates, tumor
positions of 4D FBCT, CBCT isocenter ( IsoCBCT ), translation from the CBCT to the planning CT
( T ), the gantry angle and phase of each projection.
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Figure 6 shows the flow chart of the generation of each of the four required pieces of
input data for the Tumor Detect algorithm. The blue boxes in the figure contain the data required
at each step for the generation of the input data in the red box. The summation of the
computation process is shown in Table 5. The type of work and the approximate cost of time are
listed for each step. Steps 1 to 3 are conducted once per patient. Other steps are conducted once
per CBCT scan. The Pinnacle-based approach switches from several platforms leading to low
efficiency and higher chances of calculation errors.
The RCF platform has direct access to the patient database which includes the planning
CT, reconstructed CBCTs, treatment plans and contours. Hence, it doesn’t need a copy of the
data in as the Pinnacle-based approach. The RCF tool also has image processing package which
include automatic image registration, generation of bitmap images, calculate centroid for an ROI
and other functions that are required in our purpose. The process of the input data generation as
listed in Table 6 is adapted to almost fully automatic which significantly improves the efficiency
of the input preparation process.
Table 5. The cost of time for each step in Pinnacle-based process. If the property of a step is manual work, it only has
manual cost and does not have automatic cost. Step 1-3 are done once for each patient, so the cost of time should be
considered separately. The automatic cost is mostly the running of ‘project’ code, which depends on the capacity of the
GPU-based server.

Steps
1
2
3
4
5
6

Manual cost

Automatic
cost

5 hours / patient

--

20 minutes

--

Manual work in
Pinnacle

1 hour

--

Matlab-based

20 minutes

10 minutes

Properties
Import planning CT image and plan with tumor
contours into Pinnacle database
Calculate the center of mass of tumor for all the
phases
Expend GTV with a uniform margin and create
new ROI for the expended GTV
Load the reconstructed daily CBCT into Pinnacle
database
Conduct rigid registration of the daily
reconstructed CBCT and the planning CT by
aligning the tumor
Generate tumor-only masked CT

Manual work in
Pinnacle
Manual work in
Pinnacle
Manual work in
Pinnacle
Manual work in
Pinnacle
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code
7

Calculate the isocenter of the daily CBCT

8

Calculate isocenter of the rotation and generate
Cliff files for the project code

9

Generate templates from the ‘project’ code

10

Obtain phase information for each projection

11

Obtain gantry angles of projections

Manual work

-1 hour

Manual work
Automatic
Project code
Matlab-based
code
RCF-based code

Total Time cost per CBCT scan

---

5 hours

20 minutes

--

3 hours /scan + 5
hours /patient

5.17 hours
/scan

Table 6. The cost of time for each step in RCF-based process.

Steps
Use a program to generate the of the input Cliff file for
1
the RCF-based tool
Download the image and plan information from the
2
PPG website
RCF-based too to do the processes 1~8,10 and 11 in
3
Table 5
4

Generate templates from the ‘project’ code

Properties
Automatic

Manual cost
20 minutes
/patient

Automatic cost
Negligible

Web download

--

10 minutes for
all the patients

RCF-based tool

--

10 min

Automatic
Project code

--

5 hours

0.3 hours /scan

5.18 hours /scan

Total Time cost per CBCT scan

3.4. Refinement of MLTM Algorithm
3.4.1. Image Processing in Projection Images
The raw projections are preprocessed before any further analysis, such as dark-flood field
correction, bowtie filter correction, dead pixel correction and noise filtering. Even with this
preprocessing techniques, the image contrast of the projection images are limited especially in
the slow gantry CBCT in which the radiation exposure/projection is less than the normal CBCT
scans. Hence, contrast enhancement in the images for better tumor visualization is performed.
The technique implement here is histogram equilibrium which enhances the image contrast by
transforming the image intensities so that the histogram of the output image matches a specified
histogram (uniform distribution here). The preprocessing process also includes the removal of
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markers in the projections to eliminate the potential bias of the markers on the template matching.
As described in Appendix II, markers are successfully removed from the projections by the
marker painting technique.
3.4.2. Templates for Template Matching
Shape and appearance of tumor templates are investigated to preserve the real tumor
boundary while minimizing introduction of artificial boundaries that may be introduced the zero
padding in the generation of masked CT outside the Ex-GTV region in the planning CT. Three
types of templates, including Ex-GTV template98, a cylinder template96, and a new padded
template developed here were studied in Appendix II. All templates are created from the
extended GTV which is GTV plus a 5 or 10 mm expansion. It is particularly important to
conduct this study for locally-advanced lung cancers other than small, well-defined and
radiosurgery eligible tumor cases. When creating DRR for tumor templates, artificial radiation
beams penetrate the tumor. Large tumors attenuate the beams more than the small tumor causing
large differences between zero and nonzero paddings. Therefore, these three types of templates
are investigated to reduce the zero padding effect. This effect can be mitigated to include more
lung tissues by increasing extended GTV expansion from 5 mm to 10 mm. However, for tumors
with large volume, the increased expansion itself introduces more noise structures in the
templates. Thus, in this dissertation, a10 mm expansion is chose for patient 2 and 3 with smaller
tumors (less than 50 cc) located in the central lung. For the remaining patients, the 5 mm
expansion was used due to large tumor volume or diffuse tumor.
Tracking results using the three types of templates are compared to the reference
trajectory generated from the validation framework in Chapter 2. The absolute difference
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between the MLTM and the reference trajectory is defined as the error. Template matching with
padded template provides the best results with an error of 3.5 mm, which is smaller than the 5.3
mm for Ex-GTV template and 6.1 mm for cylinder template. Similar as the numbers, in Figure 8
to Figure 12, the mismatch of the template matching with the marker reference is most severe
with Ex-GTV template and the template matching with padded template best matches the marker
reference.
3.4.3. Search Region of Template Matching
Even with the use of padded template, there are still large errors left in MLTM. The
search window in the projection imager plane is fairly large, ±2.25 cm, accounting for a potential
large motion of 3 cm (such as a deep breath). Hence, a way to narrow down the search window
effectively is of interest. One possible approach is to refine the template matching search
window with the velocity of tumor movement. The velocity may be up to 4 cm/s and with the 5
Hz frequency for projection scanning, the tumor movement between two neighboring projections
is up to 8 mm at the global coordinate leading to a ±12 mm search window to the tumor position
in the previous projection. This search window is still fairly large and the errors will propagate
from one projection to the other. Hence, this approach is not pursued. A constraint method is
introduced in Appendix II and is summarized in the following. Because the intended application
of the MLTM algorithm is not for real-time applications but for retrospective review, the tumor
trajectory obtained from a first pass of the MLTM algorithm can be considered as the training
data to generate an average cycle (mean tumor position of each breathing phase), which is used
as the guidance for a second pass of the template matching. A narrower search window is placed

42

at the phase mean tumor position, so that the chance of getting true template matching position
increases.
The size of the restricted search window is estimated from analyzing of marker
trajectories segmented from projections. For a marker in a CBCT scan, trajectory M is
segmented in projections P . Let m p , m p  M to be the marker coordinates of a single
projection p , p  P . P is grouped into 10 phases bins based on the SI marker positions, phase

i projection group denoted as P i . For projection group at phase i , the mean marker position M i
is calculated. For a projection p , p  P , a phase j is determined from the in-house phase
sorting algorithm. The difference  p between the instantaneous marker position m p and the phase

j mean marker position M j is calculated:

 p = mp  M j

(12)

Figure 7. Probability density functions (PDF) of E (blue dots) and their fitted Gaussian curves (red curve). Plots (1),
(2) and (3) are at LR, AP, and SI directions respectively. E are calculated for all the available marker trajectories,
about 6 trajectories per patient.



The differences E   p , p  P1 ,  p , p  P2 ,



p

, p  P

S

 , where S is the total number of

marker trajectories. The standard deviation of  ,   E and the interval included 97% of  in E
are computed. The distribution of  is close to Gaussian distribution as shown in Figure 7.
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The standard deviations,  are 0.6/0.9/1.7 mm in the LR/AP/SI directions, respectively, and
the 97% interval is ±1.4/±2.1/±4.0 mm. The search windows decided by either the 2.5
(1.5/2.25/4.25) or the 97% interval are close to each other. Therefore, the search window of ±3
mm at the u (across the imager panel) and ±6 mm at the v direction (along the imager panel) is
applied to the phase mean tumor position in Appendix II. As shown in Figure 8 to Figure 12, the
constraint method eliminates large jumping errors and improves the match between the results of
MLTM and the reference compared to the non-constraint methods.
3.5. Conclusion
The effect of the artificial boundary created by zero padding in the generation of masked
CT is reduced by padded template which is selected as the tumor template for further study. The
constraint method is able to reduce the search window in the template matching and improve the
matching results.
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Figure 8. Patient 1 first fraction CBCT. (1) Breathing curves comparison at SI direction (2) Error comparison at SI
direction.
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Figure 9. Patient 2 first fraction CBCT. (1) Breathing curves comparison at SI direction (2) Error comparison at SI
direction.
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Figure 10. Patient 3 first fraction CBCT. (1) Breathing curves comparison at SI direction (2) Error comparison at SI
direction.
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Figure 11. Patient 4 first fraction CBCT. (1) Breathing curves comparison at SI direction (2) Error comparison at SI
direction.
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Figure 12. Patient 5 first fraction CBCT. (1) Breathing curves comparison at SI direction (2) Error comparison at SI
direction.
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4. MLTM Considering Target Deformation

4.1. Introduction
In the previous chapter, the MLTM algorithm considers tumors with minimal shape or
volume change. Patients studied by this dissertation underwent treatments last up to 7 weeks, so
there is a high chance that tumor will deform due to natural growth of the tumor or treatment
response. Shape and volume of a tumor at the treatment day vary from the planning tumor,
especially near the end of the treatment course. Compared to the pretreatment tumor volume on
planning CT, tumors regressed 30% to 65% at the end of the treatment for patients involved in
this dissertation.

If shape and volume of a tumor change too much at the treatment day

compared the planning CT, the algorithm may fail. In previous chapter, templates are directly
made from pre-treatment planning FBCT. The MLTM with those templates is not able to obtain
correct results for fractions with large tumor deformation, because the tumor in the template
differs too much from the daily tumor. Therefore, the next major aim of this dissertation is to
adapt the MLTM algorithm for tumors with large shape or volume change.
The key issue for the adaptation of the template matching is how to generate a set of
templates that represent the daily tumor shape. Rescanning and re-delineating the patient with
FBCT is one option. But it is too costly, both in time and resources. The other option is to
generate tumor templates from the delineated daily CBCT. However, the image quality of
CBCT is low, and the tumor definition for the DRR generation requires high image quality. A
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way to transform the planning tumor to the daily tumor is considered in this thesis to
accommodate the need to obtain tumor templates with the daily tumor shape while maintaining
the image quality. Different image registration methods are performed to register the planning
CT to the daily CBCT by aligning tumor. In the following, how to deform the planning tumor
and whether the target transformation is adequate for markerless tracking near the end of the
treatment course will be investigated.
4.2. Transformation of Planning Target
In order to segment the tumor correctly in a MP by template matching, shape and size of the
tumor on its corresponding TT should as similar as on MP. TT (2D) is generated from the
masked CT (tumor-only CT, 3D) as mentioned in section 3.2.2. Hence, the problem is
equivalent to that the tumor on the masked CT (masked tumor) should match the tumor on
reconstructed daily CBCT (daily tumor). The proposed solution is to transform the tumor on the
masked CT to match the daily tumor. The transformation is obtained by image registration
between the planning CT and the daily CBCT. In Chapter 3, this transformation is rigid meaning
no shape, size and intensity change of masked tumor compared to the planning tumor. Nonrigid or deformable transformation is needed to apply to the planning tumor to deal with shape
and volume change. Both affine transformation and B-Spline DIR, which are introduced in
section 2.3, are applied to register the planning CT and the daily CBCT to the tumor. The
resulting transformations from the image registrations are applied to the masked CT, and the
transformed masked CT is used to create TT for template matching. Affine transformation
accounts for tumor expansion or shrinkage and DIR transforms the tumor in a more complex
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way. The transformed tumors of the two approaches are examined visually to check whether the
tumors align properly.
A study is conducted to determine which method is selected to deform the tumor by comparing
the tracking results of transforming the masked CT with rigid image registration, affine
transformation and B-Spline DIR. As described in Chapter 2, the average CT of the free
breathing planning CT and average CBCT are registered and the resulting transformation is used
to transform the phase images. The image quality of the CBCT phase images is poor and hence
the average CBCT is used to obtain better registration results. The spacing of the grid for
defining control points is 8.0, 4.0, 2.0, and 1.0 voxels. The DIR is running at multi-resolution
with down-sampling and the resolution pyramid is 8.0, 4.0, 2.0, and 1.0 voxels. The rest of the
MLTM algorithm uses the method selected in Chapter 3 (padded template + constraint method).
The study is performed on the last weekly CBCT of each patient in which shape and volume of
the target changes most. Table 7 shows that rigid registration is not adequate for fractions near
the end of the treatment course. However, the affine transform does not improve the results as
listed in Table 8. The trajectories of the MLTM using B-Spline DIR are shown in red curves in
the bottom plots of figures from Figure 21 to Figure 25 (the blue curves are the reference
trajectories). The accuracies are calculated in
Table 9. As suggested in the tables and the figures, B-Spline DIR improves the tracking
results substantially and provides promising accuracy.
Table 7. Errors of MLTM when the masked CT is rigidly transformed.

Rigid
Patient
1
2

Absolute Error/mm
LR
AP
SI
1.0
5.5
2.8
3.8
6.7
4.1

LR
1.4
6.0
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STDV/mm
AP
7.7
10.3

SI
3.9
6.2

90% Error Level/mm
LR
AP
SI
2.2
12.8
4.7
12.0
21.0
14.0

3
4
5
Mean

7.4
1.6
3.3
4.1

1.7
2.0
4.7
4.6

5.2
1.8
4.6
3.9

1.8
2.5
1.3
3.1

1.6
0.9
2.3
5.9

4.9
2.5
5.3
4.7

9.6
4.2
4.9
7.5

3.7
3.3
7.3
11.7

9.2
4.0
10.8
9.3

Table 8. Errors of MLTM when the masked CT is transformed by affine transformation.

Affine
Patient
1
2
3
4
5
Mean

Absolute Error/mm
LR
AP
SI
0.9
5.3
2.5
2.8
5.7
3.3
4.4
4.0
4.7
4.6
1.4
2.1
6.6
10.7
7.5
4.3
6.2
4.5

LR
1.2
4.8
1.6
2.5
1.5
2.7

STDV/mm
AP
7.8
9.3
3.4
0.9
13.1
8.1

SI
4.4
4.8
5.2
2.5
8.5
5.4

90% Error Level/mm
LR
AP
SI
1.8
12.3
6.4
8.0
15.0
7.7
5.8
6.8
8.7
6.6
2.5
4.1
8.9
21.8
16.3
6.7
13.4
9.6

Table 9. Errors of MLTM when the masked CT is transformed by B-Spline DIR.

B-Splines
Patient
1
2
3
4
5
Mean

Absolute Error/mm
LR
AP
SI
0.7
1.9
0.7
0.3
0.7
1.1
1.5
1.6
1.3
1.6
0.6
1.0
2.4
1.2
2.1
1.5
1.3
1.3

LR
0.6
0.2
0.6
0.3
1.1
0.6

STDV/mm
AP
0.8
0.7
1.2
0.7
0.9
0.9

SI
1.0
0.8
1.8
1.3
2.7
1.7

90% Error Level/mm
LR
AP
SI
1.3
2.5
1.6
0.5
1.4
2.1
2.2
3.6
3.0
1.9
1.2
2.1
3.8
2.2
4.8
2.2
2.3
2.9

4.3. Conclusion
Affine transformation fails to provide an accurate target registration. Transforming masked
CT by B-spline DIR results in best tracking results, 1.5/1.3/1.3 mm at LR/AP/SI directions. The
transformed masked tumor matches well to the daily tumor in shape and volume therefore Bspline DIR should be conducted to the planning CT in the process of MLTM.
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5. Result Analysis of MLTM

5.1. Introduction
The major goal of this thesis is to produce a method that is better than 4D CBCT in
estimating tumor trajectory. The algorithm is developed in Chapters 3 and 4 along with
Appendix II. How the algorithm performs and whether it outperforms 4D CBCT is a question
yet to be answered. Hence, the next major aim of the thesis is to analyze to accuracy of the
MLTM algorithm and compare against 4D CBCT. The major contribution of this chapter is to
analyze the results of MLTM in the following ways. Firstly, the tracking errors of each scan of
every patient are calculated and studied. Due to the rotation geometry of the CBCT projections,
the tracking results are expected to be different at different gantry angles. The correlation of the
tracking errors and gantry angle are studied to determine whether the errors correlate consistently
among patients with the gantry angles. If there is a correlation, certain gantry angles with larger
tracking errors can be avoid to be used in the creation tumor trajectory or pdf of tumor motion.
Secondly, the markerless tracking algorithm is compared against the clinical standard 4D CBCT.
The full trajectory of MLTM and the 4D CBCT are compared and the errors are calculated. In
the following, angular correlation of tracking errors and whether MLTM outperforms 4D CBCT
will be determined.
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5.2. Angular Error Analysis
MLTM is performed on projection images which are planer image rotating with the rotation
of the gantry. For the images evaluated here, the gantry rotated during CBCT acquisition from 180ºto 180º, or the opposite. Image at 0ºis AP view, 180º(or -180º) is PA view, 90ºis RL view
and -90ºis RL view. The errors are defined as the absolute difference between the MLTM
trajectories and the reference trajectories obtained from Chapter 2. Figure 16 to Figure 20 plot
the errors of the MLTM trajectories at the SI direction against gantry angles of the 5 patients.
For statistical analysis, projections are grouped in 36 groups by gantry angles with an interval of
10º. Projections with gantry angles from -180ºto -170ºbelong to group 1, where the mean
gantry angle -175ºis the gantry angle of the group, and projections with gantry angles from 170º
to 180ºbelong to group 36, whose group gantry angle is 175º. Analysis of variance (ANOVA)
test is used to evaluate if there was any relationship between the mean errors of the 36 groups of
projections with the gantry angles. Figure 13, Figure 14 and Figure 15 are the results of
ANOVA test at LR, AP and SI directions. The p values of these 3 tests are all less than 0.0001.
Therefore, there are significant difference between groups and the tracking errors are gantry
angle dependent. As the gantry rotates, the contrast of tumor differs because the length of
tissues or bones that the radiation beams penetrates are different at different gantry angles. The
errors are generally worse at oblique angles such as -135º, -115º, -35º, 25º, 35ºand 105º. The
number of outliers (outside the blue lines in figures from Figure 16 to Figure 20) for each group,
which are errors lying outside region [-2, 2] mm, is greater at gantry angles from -150ºto -110º
and -60ºto -30ºfor patients 1, 2, 3 as well as 5, especially patient 3, and from 10ºto 40º, 100ºto
120º, 140ºto 150ºfor patient 4. These results are consistent to the ANOVA results. These
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oblique angles are between lateral and AP/PA views, where beams penetrate more bony
structures (ribs) leading to worse results.

Figure 13. ANOVA test results for LR components of absolute errors with gantry angle grouping. For each group,
the mean gantry angle is used to represent the group. The central of the box indicates the median value of the group
and the lower and upper boundary line of the box are at the 25%/75% quantile of the data. The tick marks represent
the outliers.
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Figure 14. ANOVA test results for AP components of absolute errors with gantry angle grouping. For each group, the
mean gantry angle is used to represent the group. The central of the box indicates the median value of the group and
the lower and upper boundary line of the box are at the 25%/75% quantile of the data. The tick marks represent the
outliers.
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Figure 15. ANOVA test results for SI components of absolute errors with gantry angle grouping. For each group, the
mean gantry angle is used to represent the group. The central of the box indicates the median value of the group and
the lower and upper boundary line of the box are at the 25%/75% quantile of the data. The tick marks represent the
outliers.
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Figure 16. Patient 1 MLTM trajectory errors at SI direction. Top is the first scan and bottom is the last scan. The dots
are the errors and the lines indicate error levels of ±2 mm.
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Figure 17. Patient 2 MLTM trajectory errors at SI direction. Top is the first scan and bottom is the last scan. The dots
are the errors and the lines indicate error levels of ±2 mm.
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Figure 18. Patient 3 MLTM trajectory errors at SI direction. Top is the first scan and bottom is the last scan. The dots
are the errors and the lines indicate error levels of ±2 mm.
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Figure 19. Patient 4 MLTM trajectory errors at SI direction. Top is the first scan and bottom is the last scan. The dots
are the errors and the lines indicate error levels of ±2 mm.
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Figure 20. Patient 5 MLTM trajectory errors at SI direction. Top is the first scan and bottom is the last scan. The dots
are the errors and the lines indicate error levels of ±2 mm.

5.3. Benchmarking MLTM against 4D CBCT
4D CBCT is the current clinical method to determine tumor trajectory for lung tumors.
Whether MLTM outperforms the 4D CBCT needs to be evaluated. The tumor trajectory
obtained from MLTM is compared against the 4D CBCT trajectory. The output of MLTM is
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tumor positions as a function of time (gantry angle) while the 4D CBCT only provides average
tumor position as a function of breathing phase. Tumors are delineated in every phase of the
reconstructed 4D CBCT resulting the average cycle of tumor positions which includes one tumor
position at each of the 10 phases. In order to conduct the comparison, the average cycle of the
4D CBCT need to be expanded to a full trajectory. Phases of all projections are predetermined.
For a projection, the average phase tumor position obtained from the 4D CBCT is used to
represent the tumor position of the projection and the computation is done for all projections.
These positions are plot against the projections’ gantry angles, resulting the 4D CBCT full
trajectory. The errors of both the MLTM trajectory and the 4D CBCT full trajectory are
calculated and compared. The errors of the MLTM trajectory and the 4D CBCT full tumor
trajectory are listed in Table 10 and Table 11. The plots of comparing full tumor trajectories at
SI direction are shown in figures from Figure 21 to Figure 25 and the average trajectories at the
SI direction by grouping projections into 10 phases are shown in figures from Figure 26 to
Figure 30. These tables and figures show that the MLTM algorithm outperforms the 4D CBCT in
3 patients (Patient 1,2 and 4) and no worse in 2 patients (Patient 3 and 5). The average
amplitude of tumor motion measured from the 4D CBCT and the markers does not always match
each other. 4D CBCT underestimates the tumor motion in several cases, for example plot (2) of
Figure 26 and plot (1) of Figure 27. The factors that may cause this disagreement are delineation
uncertainties, phase sorting deficiency of 4D CBCT and 4D CBCT reconstruction artifacts.
Table 10. Errors of tumor trajectory obtained from MLTM.
Absolute Error
Patient
1
2

st

1
scan

STDV

90% Error Level

x

y

z

x

y

z

x

y

z

0.9

1.2

1.0

0.5

1.2

1.2

1.5

2.5

2.2

0.5

0.5

1.0

0.6

0.6

0.7

1.1

2.0

1.9
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Absolute Error
Last
scan

STDV

90% Error Level

x

y

z

x

y

Z

x

y

z

0.7

1.9

0.7

0.6

0.8

1.0

1.3

2.5

1.6

0.3

0.7

1.1

0.2

0.7

0.8

0.5

1.4

2.1

3

0.5

1.4

1.8

0.7

1.1

2.1

1.1

2.7

3.9

1.5

1.6

1.3

0.6

1.2

1.8

2.2

3.6

3.0

4

1.8

0.8

2.2

0.5

0.9

2.3

2.6

1.6

4.7

1.6

0.6

1.0

0.3

0.7

1.3

1.9

1.2

2.1

5

1.4

2.0

2.6

1.3

1.4

3.3

2.8

3.5

5.8

2.4

1.2

2.1

1.1

0.9

2.7

3.8

2.2

4.8

Mean

1.1

1.3

1.8

0.8

1.1

2.1

2.0

2.5

4.0

1.5

1.3

1.3

0.6

0.9

1.7

2.2

2.3

2.9

Table 11. Errors of 4D CBCT full tumor trajectory.
Absolute Error

90% Error Level

Absolute Error

x

y

z

X

y

z

x

y

Z

x

y

Z

x

y

z

x

y

z

1.1

3.1

3.0

0.4

1.1

1.4

1.5

4.4

4.6

2.8

3.5

2.1

0.8

1.0

1.3

3.8

4.7

3.6

0.8

2.0

1.6

0.7

1.0

1.8

1.6

3.4

3.2

1.7

0.7

1.3

0.6

0.8

1.4

2.4

1.5

2.9

0.9

0.9

1.0

1.0

0.6

1.3

1.8

1.6

2.2

6.1

1.2

1.5

0.5

0.5

1.8

6.9

1.9

3.4

4

2.3

1.4

3.1

1.3

1.3

3.9

3.6

2.5

6.2

2.2

2.2

2.0

0.4

0.8

2.0

2.7

3.3

3.8

5

3.4

1.2

2.0

1.0

1.1

2.3

4.6

2.4

4.1

4.0

2.2

3.7

1.1

0.7

1.9

5.4

3.1

6.3

Mean

2.0

1.9

2.3

0.9

1.0

2.3

2.9

3.0

4.3

3.7

2.2

2.3

0.7

0.8

1.7

4.6

3.1

4.2

Patient
1
2
3

st

1
Scan

STDV
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Last
Scan

STDV

90% Error Level

Figure 21. Patient 1 trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT full
trajectory, red curve is the MLTM trajectory, and blue curve is the reference trajectory. The top plot shows the
trajectories of the first scan and the bottom plot shows trajectories of the last scan.
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Figure 22. Patient 2 trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT full
trajectory, red curve is the MLTM trajectory, and blue curve is the reference trajectory. The top plot shows the
trajectories of the first scan and the bottom plot shows trajectories of the last scan.
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Figure 23. Patient 3 trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT full
trajectory, red curve is the MLTM trajectory, and blue curve is the reference trajectory. The top plot shows the
trajectories of the first scan and the bottom plot shows trajectories of the last scan.
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Figure 24. Patient 4 trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT full
trajectory, red curve is the MLTM trajectory, and blue curve is the reference trajectory. The top plot shows the
trajectories of the first scan and the bottom plot shows trajectories of the last scan.
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Figure 25. Patient 5 trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT full
trajectory, red curve is the MLTM trajectory, and blue curve is the reference trajectory. The top plot shows the
trajectories of the first scan and the bottom plot shows trajectories of the last scan.
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(1)

(2)

Figure 26. Patient 1 average trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT
average trajectory, red curve is the MLTM average trajectory, and blue curve is the reference average trajectory.
The left plot shows the trajectories of the first scan and the right plot shows the trajectories of last scan.

(1)

(2)

Figure 27. Patient 2 average trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT
average trajectory, red curve is the MLTM average trajectory, and blue curve is the reference average trajectory.
The left plot shows the trajectories of the first scan and the right plot shows the trajectories of last scan.
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(1)

(2)

Figure 28. Patient 3 average trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT
average trajectory, red curve is the MLTM average trajectory, and blue curve is the reference average trajectory.
The left plot shows the trajectories of the first scan and the right plot shows the trajectories of last scan.

(1)

(2)

Figure 29. Patient 4 average trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT
average trajectory, red curve is the MLTM average trajectory, and blue curve is the reference average trajectory.
The left plot shows the trajectories of the first scan and the right plot shows the trajectories of last scan.
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(1)

(2)

Figure 30. Patient 5 average trajectories comparison at SI direction. The green curve in each plot is the 4D CBCT
average trajectory, red curve is the MLTM average trajectory, and blue curve is the reference average trajectory.
The left plot shows the trajectories of the first scan and the right plot shows the trajectories of last scan.

5.4. Conclusion
The tracking results are not as good at some gantry angles. One may avoid use data from those
angles as to form the final tumor trajectory. The results also indicate that MLTM is at least not
worse than 4D CBCT and it outperforms 4D CBCT in sum.
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6. Discussion and Conclusions

6.1. Discussion and Conclusions
This dissertation is focused on the development of a temporal markerless lung tumor
trajectory estimation algorithm with clinical acceptable accuracy. By this, one is able to
characterize the patient-specific tumor motion pattern, which outperforms 4D CBCT without the
need for invasive fiducial implantation. The resulting tumor motion pattern is a crucial input
component for generating patient-specific GTV to PTV margin in adaptive radiotherapy and
incorporating variability models into 4D inverse treatment planning. The reduced margin
treatment plans could spare more normal tissue or escalate the dose prescribed to the tumor.
This motivated the implementation and development of MLTM as the primary focus of this
dissertation. Chapter 1 introduced the rationale for the research problem and intended research
design.
As a reliable validation method is lacking, a validation framework based on fiducial markers
is developed and evaluated in Chapter 2 to assess MLTM. TMD_DIR is selected to correct the
segmented marker trajectory to tumor trajectory as the reference. The accuracy of the validation
framework is 1.8 mm, indicating that TMD_DIR + marker trajectory is a reliable validation
method for MLTM. The major limitation is that the calculation of the uncertainties is based on
the assumption that the physician delineation is the ground truth. However, the delineation itself
introduces uncertainties. In this study, the patients are delineated by one physician, so inter74

observer variability is not considered. Ideally, the intra-observer variation of tumor delineation
could be separately quantified to enable calculation of uncertainties. It is not separated from the
inter- and intra-fractional variation due to the overall small magnitude of the total variability.
MLTM is developed and improved to acquire tumor trajectory with clinical acceptable
accuracy for lung patients with locally advanced lesions in Chapter 3 and Chapter 4. The
development is separated into two parts by whether considering tumor deformation. The first
development (Chapter 3) is taken place on the first available weekly CBCT under the assumption
that time is not a variable in consideration meaning that tumor is with minimal or none
deformation. Shape and appearance of the template is investigated, and 3 types of templates
(Ex-GTV template, cylinder template, and padded template) are studied and compared. A
constraint method is introduced to constrain template matching searching region for more precise
matching results. Padded template is selected as the template and the constraint method further
reduce the tracking errors from 3.5 mm to 2.1 mm. The second part (Chapter 4) is to
accommodate the MLDM to account for time influence which is tumor deformation due to
treatment response for the later fraction CBCT. B-spline DIR is demonstrated to be accurate and
adequate to transform masked CT for the generation of TT in MLDM and the accuracy is 2.4
mm.
In Chapter 5, the results of MLDM are analyzed and compared against 4D CBCT.
Statistically, gantry angles affect the tracking results. At gantry angles from -150ºto -110º, -60º
to -30º, the MLDM algorithm has worse results. At these angles, radiation beams penetrating
more bony structures (ribs) than other angles and the tumor contrast is poorer. MLDM is at least
not worse than 4D CBCT and outperforms 4D CBCT in summary.
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One limitation of MLDM is the tumor contrast. One direction of the future work will be
developing a robust method to improve tumor contrast. A challenging task will be adapting the
algorithm to real time. The latency due to the computation time of the algorithm and how to
acquire daily tumor information before the daily CBCT will be the main concern.
6.2. Original Contributions
In this dissertation, specific contributions include:
(1). A marker painting technique is employed to eliminate the effect of markers on template
matching as stated in Appendix I. Fiducial markers are implanted in the patients inside
the tumors. They are radiopaque and with high intensity contrast in radiographic images.
When conducting template matching of planning tumor to daily tumor, the existence of
marker inside the tumor may bias the results. An interpolation based marker painting
technique is developed to remove markers from every projection image of a CBCT scan.
The technique successfully removes markers and reduces the effect of markers on
template matching by both phantom and clinical observations.
(2). A new method to validate markerless tracking algorithm is developed and investigated in
this work. The validation framework is based on fiducial markers that implanted inside
or near the tumors. The details of the framework development are introduced in Chapter
2. The validation method is with acceptable accuracy and is employed in the result
analysis in this dissertation.
(3). A new type of tumor template, padded template, is introduced and compared to the
existing templates, i.e. Ex-GTV template and cylinder template in Chapter 3. Padded
template is edited in the gradient map of Ex-GTV template. This editing is more direct
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and results in more accurate definition of tumor in tumor template. The results support
this statement and they show that the tracking errors are much smaller by using padded
template.
(4). A novel prediction method is developed to constrain the search region for template
matching to obtain better matching results in Chapter 3. The method is developed under
the condition that it is a retrospective study. The method iterates the process of MLTM
twice. The first running is considered as the training data to obtain an average breathing
cycle which is considered as the predicted position in the second running. This method is
able to reduce the search region in the template matching process and provides more
accurate tracking results.
The author also makes contributions in improving the efficiency of computation, development
and writing of the codes, data collection of marker segmentation, as well as bug detection of
RCF library.
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ABSTRACT
Purpose: To develop and evaluate a validation framework for image-based markerless target tracking
algorithms.
30

Methods: Fiducial markers were implanted inside or near the gross tumor volume in six locally-advanced
lung cancer patients, who underwent planning 4D fan beam CT and repeat 4D cone beam CT. The 3D
marker trajectories were reconstructed from CBCT projections to quantify tumor motion during scan
acquisition. The tumor was delineated in a subset of the reconstructed 4D CBCT scans. A correction
based on the tumor-to-marker displacement (TMD) was applied to the marker trajectory to generate the

35

reference tumor trajectory. The variability of the TMD over the treatment course was measured, and the
uncertainty of the entire validation framework was estimated.
Results: The uncertainties of the TMD were 0.2/1.0/1.7 mm, for the left-right/anterior-posterior/superiorposterior directions, respectively, for delineated CBCTs. Using linear models to fit undelineated CBCTs,
the uncertainties of the TMD were 1.2/1.1/2.1 mm.

40

Conclusions: The framework of marker-based delineation-free validation method was demonstrated to be
an accurate method to estimate tumor centroid positions and hence could be used to validate image-based
markerless target tracking algorithms.

I.
45

INTRODUCTION

Algorithms to locate lung tumors directly in sequential 2-dimensional (2D+t) data sets such as cone beam
CT (CBCT) projections or fluoroscopy are in active development, but a method to validate them in
clinical data other than phantom studies is lacking. Instead, some validation studies1 rely on manual
segmentation of the target in 2D images, which is limited to comparisons in small datasets by the timeconsuming nature of the segmentation. Other studies compare the result of the markerless tracking
2

50

algorithm to an average target trajectory from 4-dimensional (4D) CBCT2,3, which does not allow for
evaluation of the quality of the tracking on short time scales and in response to cycle-to-cycle variation.
Fiducial markers implanted near or inside the tumor may provide a 3-dimensional (3D) reference tumor
trajectory throughout the whole CBCT scan. However, lung tumors often change shape and volume
during therapy, which may impact the utility of the fiducial markers as a long-term surrogate for tumor

55

position and trajectory. We propose to calibrate the fiducial marker trajectory to the tumor position using
a combination of 2D+t and 4D image data. The purpose of this study is to develop and evaluate a markerbased validation framework to estimate the position of the tumor in 2D+t data sets for validation of
registration or tracking algorithms.

II.

METHOD
II.A.

60

Patient Data

Under an institutional review board-approved protocol and after providing informed consent, 2-3 fiducial
markers (Visicoil, RadioMed Corporation, Tyngsboro, Massachusetts) were implanted bronchoscopically
in or near the tumor prior to simulation for 6 lung cancer patients set to undergo conventionallyfractionated radiation therapy. All patients were treated with 3D conformal RT (62.6-70 Gy) with
65

standard fractionation (1.8-2 Gy, five days per week). 4D CBCT was acquired daily for each fraction of
the treatment for each patient. The gross tumor volume and any implanted fiducial markers were
contoured by a physician on each phase of a 4D planning fan beam CT (4D FBCT) and several (generally
weekly) 4D CBCT for all the 6 patients.

II.B.
70

Validation Framework

The validation framework is designed to benchmark image-based markerless tracking algorithms which
perform rigid measurement of tumor position, since tumor deformation during free breathing is assumed
to be small. Based on this assumption, the tumor position during free breathing acquisition of a single
CBCT is well-described by measurement of the tumor centroid. Therefore, a marker implanted near the
3

tumor centroid should describe the instantaneous translational motion of the tumor centroid, provided the
75

offset between the tumor centroid and marker positions is known. However, day-to-day changes in shape
and volume of the tumor will cause this offset, which we term the tumor to marker displacement (TMD),
to vary on a day to day basis. The basic structure of the validation framework is to use the implanted
marker trajectory to represent the tumor trajectory during a single CBCT scan. Then, the TMD is
measured from the delineated tumor and markers on the reconstructed 4DCBCT images. The TMD over

80

several fractions is then fit to a model to estimate residual uncertainty (i.e., tumor delineation and other
factors) and enable TMD estimation for undelineated CBCT scans.

The implanted markers are segmented in each 2D projection of a CBCT scan using a template-matching
algorithm4, which results in the full 2D marker trajectory throughout the CBCT scan. A maximum
85

likelihood estimation algorithm5 is applied to estimate the instantaneous 3D position of each marker
(denoted as m p , where p  (0,1, 2,3, ) is the projection index) in each projection during a CBCT scan.
A single marker identified as closest to the tumor centroid on the planning CT is chosen to reconstruct the
reference tumor trajectory when there are more than one marker detected in the projection images. Tumor
centroid positions differ from the marker positions. Corrections needs to be applied to the known 3D+t

90

marker trajectory m p on a set of projections in order to obtain the reference 3D+t tumor trajectory
(denoted as t p ) of the same projections. Assuming TMD is constant in the domain of  , the definition is:

TMD( )  T ( )  M ( )

(1)

where  is the collection of projections used for calculation, T is the mean tumor position and M is the
mean marker position in the domain of  . The reference t p is then calculated from:

t p  TMD( )  m p

4

(2)

TMD needs to be computed daily because it varies interfractionally, up to 1.0 cm difference, as stated in
95

Roman et al 6. For the delineated CBCTs, T is estimated from the centroid of the delineated tumor
contour (denoted as Tc ). M is calculated from the directly segmented marker trajectory m p , denoted as

M s . Substituting Tc and M s in equation (1) will produce TMDs for the delineated scans (denoted as
TMDc). For the non-delineated daily CBCT scans, one approach to calculate the TMD was from a linear
model created from the known TMD in the delineated weekly CBCTs, assuming a slow, continuous
100

change of the TMD due to slow, continuous change in tumor volume and shape during therapy. Given all
the known TMDc with the scan days denoted as D (the scan day of the planning CT is considered as day
1), TMDin is calculated using the linear regression method with least square difference criterion from the
known data:

TMDin = α  βd

(3)

where d is the scan day of the CBCT relative to the planning CT(day 1), α and β are variables computed
105

from the minimization of the sum of squared residuals.

II.C.

Framework Uncertainties

The total uncertainty of using markers to estimate tumor positions includes the uncertainty of the
estimation of 3D positions of the markers from 2D segmentations (  seg ), the intrafractional uncertainty of
tumor-to-marker displacement (  intra ), the interfractional variation of tumor-to-marker displacement
110

(  inter ) for non-delineated CBCT scans, and the observer variability in tumor and marker delineation in
the 4D CT scans. Based on the method of framework construction, this observer variability is already
included in the variabilities  intra and  inter . The uncertainty of the estimated 3D marker positions is
obtained from study Poulsen et al.5, as the same implementation was used. At the image frequency of 4D
CBCT,  seg is 0.4/0.4/0.4 mm at left-right (LR)/anterior-posterior (AP)/ superior-inferior (SI) directions
5
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respectively 7. To estimate the value of  intra , the tumor-to-marker displacements are calculated for each
phase of each delineated 4D CBCT scan. As a measure of intrafractional variability between the tumor
and markers, the standard deviation of the tumor-to-marker displacements over the 10 phases is calculated
for each scan of each patient, and  intra is calculated as the root-mean-square of the standard deviations.
The value of the interfractional variation  inter for non-delineated CBCT scans was estimated from the
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residual errors of TMDin as follows: The difference between TMDin and the measured displacement
TMDc was calculated in each delineated CBCT and defined as the residual error. The root mean square
of the residual errors (RMSE) was calculated as a measure of  inter . The total uncertainty of the
validation framework (  ) was calculated using the equation below:
2
2
2
   seg
  intra
  inter

(4)

III. RESULT
125

The standard deviation (SD) of intrafractional TMD of each patient was shown in Table 1 and  intra was
1.5 mm at SI direction. The SD at LR and AP directions are close to 0.0 mm.
TMDc were calculated for the planning CT and all delineated CBCT scans for all 6 patients, and their SI
portion are plotted in Figure 1. The root mean square of the residual errors (RMSE) of TMDin is
calculated for each patient and shown in Table 2. The interfractional uncertainty of tumor-to-marker

130

displacement (  inter ) for non-delineated CBCT scans is 1.2/1.3/2.0 mm at LR/AP/SI directions
correspondingly. Therefore, the total uncertainty of the validation framework (  ) was estimated to be
0.2/1.0/1.7 mm from the calculation using equation (4) for delineated CBCT scans and 1.2/1.6/2.6 mm for
non-delineated scans at LR/AP/SI directions correspondingly.
The validation framework was tested in the second weekly CBCT scan of patient 1 as an example. The
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trajectory obtained from a markerless tracking algorithm2 was compared against the reference trajectory

t p . The markers were removed from the projection images using an in-painting technique so as not to
6

bias the markerless algorithm. The trajectories comparison at the SI direction is shown in Figure 2. The
error was defined as the difference between the markerless trajectory and the reference trajectory from the
validation framework. The mean absolute error was 1.7 mm with the standard deviation 1.6 mm and 90%
140

error level was 3.3 mm.

IV. DISCUSSION
The marker-based validation framework, which employs TMD as the correction factor to generate
reference tumor trajectory for the markerless tumor tracking algorithm, has an uncertainty less than 2 mm
if the CBCT is delineated. Ideally, every CBCT should be delineated. But our study shows that, if the
145

CBCT are delineated weekly, the validation framework still has promising accuracy, less than 3 mm. The
intrafraction variability in TMD was 1.5 mm in the SI direction and negligible in other directions,
supporting our assumption of minimal deformation of the tumor to marker configuration during free
breathing. In the calculation of TMD, the marker trajectories estimated directly from the projections are
used to compute mean marker position rather than the marker contours in the delineated CBCTs. One
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reason is that markers close to each other may not be distinguishable from each other in the reconstructed
CBCT, resulting in one contour for more than one marker. The other concern is that the volume average
effect is more severe for small objects like markers resulting larger delineation uncertainty, thus the
higher spatial resolution of the projection images is preferred. In the computation of the linear function to
calculate TMD for non-delineated CBCT scans, the planning CT was not taken into account in the model.
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As shown in Figure 1, the TMD in the planning CT lies far away from the linear curve especially for
patients 4, 5 and 6. This result could be due to actual changes in tumor volume or shape, marker
migration in the generally two weeks between planning and treatment, or differences in observer
variability due to different image quality between 4DCBCT and 4D fan beam CT. In one patient, patient 6,
marker migration happens and the marker existed at the first five weekly CBCT disappeared at the sixth
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weekly CBCT. Because of the migration, the TMD at the fifth week is drifted away from the linear
model, and it is considered as the outlier as shown in Table 2 and Figure 1(f). If the outlier is not
7

removed from the linear model, the residual errors are fairly large which are 1.0/3.0/3.7 mm in the
LR/AP/SI directions respectively. In this case,  inter is reduced to 1.2/0.5/1.3 mm as shown in the brackets
in Table 2 and consequentially  is reduced to 1.2/1.1/2.1 mm.
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In the calculation of the resultant TMDs and the uncertainties, our results are based on the assumption that
the physician delineation is the ground truth. However, the delineation itself introduces uncertainties into
the framework, which manifests as an increase in

 . In this study, the patients are delineated by one

physician, so inter-observer variability is not considered. Ideally, the intra-observer variation of tumor
delineation could be separately quantified to enable calculation of the variability due to the TMD
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component alone. However, we did not separate the intra-observer variation from the inter- and intrafractional variation due to the overall small magnitude of the total variability.

V. CONCLUSION
A framework of using implanted marker and a combination of 2D+t and 4D imaging for the validation of
image-based lung tumor tracking algorithms was developed. The estimated uncertainty of the validation
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framework is 2-3 mm, depending on whether the tumor is delineated in the 4DCBCT scan or its position
is interpolated from delineated scans. In conclusion, the framework of marker-based validation method is
demonstrated to be an accurate method to estimate tumor centroid positions and hence can serve as the
validation method for image-based target tracking algorithms.
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Figure 1 (a) to (f) are the plots of tumor to marker displacement as a function of time for all 6 patients.
The red squares are the TMDc for the planning CT (day 1) and all the delineated CBCTs and the straight
line with the equation are the linear fit curve for TMDin. ............................................................................. 2
Figure 2. Example comparison of tumor trajectories measured by the validation framework and a test
185

markerless tracking algorithm, superior-inferior (SI) direction over gantry angles -150ºto 30º.................. 2
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Table 1. Intrafractional standard deviation of TMD for all delineated 4D CBCT scans, SI direction for each patient.

Patient
1
2
3
4
5
6
Total
(intra)

1
0.7
0.7
1.2
2.1
1.8
4.0

Intrafraction standard deviation of TMD (mm)
2
3
4
5
6
1.3
0.6
1.1
1.0
0.8
0.5
0.8
0.9
0.5
-0.8
0.9
1.0
0.8
0.4
2.5
1.3
2.6
1.7
1.3
0.9
1.2
0.7
0.9
1.0
2.1
2.0
1.4
2.0
-1.5
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Table 2. RMSE of Linear Model.

RMSE (mm)
LR
AP
0.5
0.3
1
1.3
0.6
2
2.3
0.3
3
0.9
0.6
4
0.3
0.6
5
0.8 (1.0*)
0.4 (3.0*)
6
1.2 (1.2*)
0.5 (1.3*)
Total (inter)
*Results for without ruling out the outlier for patient 4.
Patient
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SI
0.7
1.9
1.6
1.3
1.3
0.4 (3.7*)
1.3 (2.0*)

7
1.0
--1.2
---

Patient 2

Patient 1

3.00

3.00
2.50
TMD/cm

TMD/cm

2.50
2.00
1.50
y = -0.0043x + 1.6108
R² = 0.5278

1.00

2.00
1.50
1.00

0.50

y = -0.0042x + 1.3167
R² = 0.7518

0.50

0.00
0

20

Day

40

60

0.00

80

0

20

Day

(a)

5.50
5.00

4.00
y = -0.0119x + 3.3606
R² = 0.8231

3.50

TMD /cm

TMD/cm

Patient 4

6.00

4.50

3.00

y = 0.005x + 3.2977
R² = 0.1852

4.50
4.00
3.50

2.50
2.00

3.00
0

20

Day

40

60

80

0

20

(c)

40

Day

60

(d)

Patient 5

3.00

Patient 6

7.50

2.50
TMD /cm

60

(b)

Patient 3

5.00

40

7.00

2.00

6.50

y = 0.0048x + 0.483
R² = 0.7787

1.50

6.00

1.00

5.50

0.50

5.00

0.00

y = -0.1109x + 9.4484
R² = 0.9993

4.50
0

20

Day

(e)

40

60

0

10

20

30
Day

40

50

60

(f)

Figure 1 (a) to (f) are the plots of tumor to marker displacement as a function of time for all 6 patients. The red squares are
the TMDc for the planning CT (day 1) and all the delineated CBCTs and the straight line with the equation are the linear fit
curve for TMDin.
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Figure 2. Example comparison of tumor trajectories measured by the validation framework and a test markerless
tracking algorithm, superior-inferior (SI) direction over gantry angles -150ºto 30º.
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Optimizing template matching-based markerless tumor trajectory estimation algorithm in lung
cancer patients
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ABSTRACT
Purpose: The purpose of this study was to optimize the markerless template matching algorithm for
estimation of the 3D tumor trajectory for cone beam CT (CBCT) projections in lung cancer patients.
Methods: Markers were planted in the patients and they were removed from the projection images
10

using Laplacian interpolation. The effectiveness of marker removal was evaluated by a phantom
study. Markerless tumor trajectory estimation uses a set of templates generated from forward
projecting a region of interest of the planning fan beam CT to match the tumor in the CBCT
projections. Three different template methods of registration were compared. One called Ex-GTV
template, generated from GTV plus a margin. One generated from the minimum bounding cylinder
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of expended GTV, called cylinder template. The last template generated from zero padding at the
gradient image of the Ex-GTV template, denoted as padded template. Errors of the markerless
template-based matching algorithm using each set of template were calculated relative to the tumor
position obtained from segmented implanted internal fiducial marker trajectories. Furthermore, a
constraint method was implemented to penalize large mis-matches.
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Results: Application of marker painting improved the registration by 2 pixels at each coordinate
compared against the gold standard. The registration errors (mean absolute error/standard
deviation/90% error level [all in mm]) obtained with five patients using the three different template
methods were 5.3/6.5/12.4 for the Ex-GTV template, 6.1/6.4/13.3 for the cylinder template, and
3.5/5.0/7.9 for the padded template. The magnitudes of errors were further reduced to 2.1/2.5/4.3
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after implementing the constraint method.

Conclusions: The marker removal technique we implemented here successfully reduced the effect of
markers on the 2D image registration. The trajectory obtained from using padded template agreed
best with the implanted marker trajectories and the constraint method further improved the results.

I.
30

INTRODUCTION
Image guided radiotherapy (IGRT) has the potential to improve targeting by incorporating

temporal patient specific geometry information and variations into the adaptive planning process1-5.
Incorporating variability models into the treatment plan, whether through 4D inverse planning or
offline adaptation, requires characterization of an individual patient’s motion pattern throughout
the treatment course. Because the patient-specific motion model is often built at the simulation
35

stage, it is inadequate to fully represent the situation during treatment delivery due to
interfractional geometry variation6,7. Therefore, monitoring tumor motion during the treatment or
retrospective evaluation of treatment plans is necessary to ensure and evaluate dose delivery.
Respiration correlated four-dimensional computed tomography (4DCT) 8-10 is able to provide 3D
anatomy at each phase of breathing and the average cycle of respiration induced organ motion.
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However, the tumor motion is not simply periodic but it suffers from cycle to cycle variation and
shift of the mean or exhale tumor position (drift) 11-13. The average breathing cycle from the 4DCT
cannot provide information to estimate cycle-to-cycle variation and drift. Hence, the instantaneous
tumor trajectory needs to be measured in order to quantify these variations. Current techniques
that are used to track the tumor can be grouped into three categories: tracking external surrogates,
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tracking with implanted internal fiducial markers, and markerless tracking with internal anatomical
features. Although external surrogates require no radiation dose and are generally straightforward
to use, the correlation between the tumor location and external surrogate signals varies within a
fraction and across treatment days14-17. Tracking implanted radiopaque fiducial markers in
fluoroscopic images and projection images of CBCT has been pursued by researchers18-25. Fiducial
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markers serve as reliable surrogate to locate or track tumors21,24. Marker implantation is invasive, so

physicians and patients are not always willing to use this procedure especially by those expecting a
‘non-invasive’ treatment modality with radiation therapy.
‘Markerless’ localization of the tumor mass in fluoroscopic images has been studied for
tracking26-28 and gating29-31. Support vector machine-based30, template-based26, and optical flow27
55

based algorithms were developed for fixed beam angle fluoroscopic detection (no gantry rotation
during acquisition). Template-based markerless tumor tracking has been extended to the case of
gantry rotation32-35. These studies evaluated small, parenchymal lesions such as those amenable to
stereotactic body radiotherapy. Here, we extend the template matching approach to larger lesions
infiltrating the chest wall, hilum, or mediastinum. We optimize the template shape for these
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challenging cases, and evaluate a method to penalize large mis-matches.

II.

METHOD

II.A. General Description of the Algorithm
A template-based matching algorithm for markerless tumor trajectory estimation (MLTM) was
developed previously 32. The procedure consists of five steps as shown in Figure 1: 1) GTV (in green)
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was delineated by physicians in the planning 4DCT and it was expanded with a margin to obtain
Expanded GTV (Ex-GTV, in purple). 2) Generation of masked CT was by zero padding regions outside
Ex-GTV and the masked CT was shifted to the daily tumor position by registering the tumor in the
planning CT to the tumor in the daily CBCT, which is denoted as the daily tumor position. 3) The
shifted masked CT was forward projected to generate digital reconstructed radiograph (DRR) at each
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phase and each gantry angle intervals and the DRRs are denoted as tumor template (TT). 4) Crop the
TT and perform 2D/2D registration of TT to the measured CBCT projections (MP) by template
matching (TM) within a search region of ±4 mm. The red contour is the matching result. 5)
Reconstruct 2D positions to generate3D tumor trajectory by backprojection.
The following simple enhancements are added to this basic framework, but are not the main focus
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of this work:

1)

Histogram equalization is applied to the search region in the projection images to improve

the contrast.
2)

The search window for template matching is adapted to ±22.5 mm, which is ±15 mm in the

room coordinates, instead of the ±4 mm window to account for the up to 3 cm tumor motion.
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3)

The similarity metric used to conduct template matching is changed from block normalized

cross correlation (NCC) to a gradient correlation metric termed the Orientation Correlation (OC) 37.
4)

A spatial probabilistic method developed by Poulsen et al36 is used to reconstruct 3D tumor

positions from 2D tumor positions other than a simple backprojection in the original framework.
The main adaptions will be introduced in section II.C.
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Five patients underwent CBCT imaging on a study approved by the local institutional review board
after providing informed consent. The studied patients were implanted with fiducial markers, and
the trajectories obtained from those markers were used to validate the markerless algorithm
(Appendix I). One CBCT scan acquired early in the treatment course was analyzed to avoid the effect
of large shape changes (i.e., tumor response) in this study.
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II.B. Marker Removal
The patients were implanted with fiducial Au markers (Visicoil, RadioMed Corporation, Tyngsboro,
Massachusetts) which were usually radiopaque and high contrast structures. The extra information
introduced by fiducial markers in projection images might influence the 2D image registration. The
marker effect should be eliminated in order to obtain markerless tracking results unbiased by
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markers, as the markers are used in the validation methodology. A marker painting technique,
which was replacing the intensity of pixels inside the marker region by the interpolation value of the
surrounding region, was implemented and evaluated.
The markers were segmented using a semi-automated algorithm25 with the output of the marker
centroid positions and 3D marker shape models. The 2D binary mask of markers (marker shadow)
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for each projection of the CBCT was generated by projecting the 3D shape model to the projection
plane. The 2D marker shadows were expanded by 2 pixels to ensure coverage of the whole marker

and relocated to the centroid positions of the markers, e.g. Figure 2g. The intensity inside the marker
mask was replaced by interpolating the value from surrounding pixels plus added white noise
sampled from a Gaussian distribution. We chose a diffusion-based Laplacian interpolation to obtain
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the interpolation values 38,39.
Marker painting was applied to both phantom and clinical images to see whether the method was
effective at marker removal. A phantom study was conducted to determine if the marker painting
technique was effective at reducing the influence of markers on the image registration. The
phantom used was a lung phantom with a tumor insert inside (QUASAR™ Cedar Lung Tumour Insert,
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Modus Medical Devices Inc., London, Canada) as shown in Figure 2a, attached to a dynamic motion
stage. The phantom images were taken at two different couch positions to conduct rigid image
registration (translation only). Five phantom projection images were taken at two couch positions
with or without markers at a fixed gantry angle as shown in Figure 2 (b) to (f). At each of the two
couch position, we took a projection image of the phantom without attaching any markers and the
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registration between these two images (Figures 2b and 2d) was considered as the gold standard. We
evaluated three registration scenarios: For Scenario 1, an image of the object with markers (Figure
2c) was registered to an image of the shifted object without markers present (Figure 2d). For
Scenario 2, images of the object with markers in the same location relative to the object (Figures 2c
and 2e) were registered. Finally, for Scenario 3, images of the object with markers in different
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orientations relative to the object (Figures 2c and 2f) were registered. These three registration
scenarios were repeated after marker painting. Registration error was measured in pixels, relative to
the result from the gold standard.

II.C. Algorithm Refinement
II.C.1.
125

Template Study

The templates were rectangular to allow usage of the fast Fourier transform (FFT) in the gradient
correlation. In the previous study32, tumor templates were generated from ROI of physician
contoured GTV plus a 5/10 mm margin in the planning 4DCT with zero padding outside the ROI,

denoted here as the Expanded GTV (Ex-GTV) template. Artificial boundary that introduced by the
zero padding in the generation of masked CT outside the Ex-GTV region in the planning CT is a
130

particularly important issue to resolve for locally-advanced lung cancers compared to small, refined
tumor cases. When creating DRR for tumor templates, artificial radiation beams penetrate the
tumor. Large tumors attenuate the beams more than the small tumor causing large differences
between zero and nonzero paddings. Therefore, three competing template-generation methods
were studied in order to resolve this issue.
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The first set of template was the Ex-GTV template (Figure 3a). The second set of templates was
generated from the minimum bounding cylinder of the ROI (GTV plus a 5/10 mm margin), denoted
here as the Cylinder template33. The templates generated from this ROI were already rectangular, so
no artificial gradient after cropping was present (Figure 3b). An additional approach to avoid the
artificial gradient was to only use pixels inside the expanded GTV region to conduct the gradient
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correlation in the template matching. But this approach is time consuming because it cannot use the
FFT in the gradient correlation. Instead, the last set of templates was generated from the Ex-GTV
template with some modification in the gradient image. The gradients outside the shape region of
the tumor of each template were padded with zero (Padded template). Figure 3d was the zero
padded gradient image of Figure 3c, which was gradient image of the Ex-GTV. The Orientation
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Correlation matched images using correlation, so pixels with zero gradients had no effect on the
matching results, and FFT could still be utilized for speed.

II.C.2.

Constraint from Training

The search margin in the template matching algorithm was ±15 mm in the global coordinate system.
This search region could be constrained since the breathing phase for a given projection was known.
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The tumor trajectory obtained from a first pass of the template matching algorithm was used as the
training data and an average cycle trajectory (mean tumor position of each breathing phase) was
generated to guide a second pass of the template registration. The mean position (  ) and standard
deviation (  ) of the tumor trajectory, which were obtained from the selected template method

based on the results of the previous section, were calculated. The portion of the trajectory which
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was within   2 was used to generate the average breathing cycle. The 3D tumor positions
chose from the average breathing cycle based on the phase of the projection were forward
projected from the global coordinate system to the 2D detector plane to obtain the 2D positions. A 3
mm margin was applied to the u direction (across the panel) of the 2D image and a 6 mm margin
was applied to the v direction (along the panel) to refine the search region of the 2D registration.
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This margin was obtained from the study of the marker trajectories. The difference between the
instantaneous marker positions and the mean marker position of the projection phase for each
projection was calculated and analyzed. The margin was chosen from the 95% interval of the
differences. The template matching was conducted at the refined search region to obtain the 2D
tumor positions.
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II.C.3.

Evaluation

The resultant tumor trajectories from the markerless estimation were compared to the gold
standard which is the tumor trajectory estimated from the marker trajectory. The errors were
calculated by the difference between the trajectories of markerless estimation and marker
estimation. The mean absolute errors, the standard deviation of the errors, and the 90% error level
170

were calculated.

III. RESULTS
III.A. Marker Removal
Figure 5 shows the clinical CBCT projections with and without marker in-painting. In case 1, the
marker was successfully visually removed from a relatively uniform background region. In case 2, the
175

marker is visible over a high contrast structure. After the marker removal, the high contrast
boundary beneath the marker region was preserved even though there was some blurring.
Figure 6 shows the CBCT projections of the dynamic phantom with and without marker in-painting.
The phantom was scanned at the same setup with and without attached markers. The projection do

not contain markers was considered as the reference which the marker removal results were
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compare against. The sharp gradient introduced by the marker was successfully removed by the
marker removal technique and the profile of the marker removed image was close to the reference
profile. For the registration aspect of the phantom study, the registration error for the three
scenarios were (-2, 0), (-2, 1) and (-3, 2) pixels correspondingly before marker removal. After
applying the marker painting technique, the registration errors were all reduced to (-1, 0).
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III.B. Algorithm Refinement
Table 1 shows the errors obtained by employing the Ex-GTV template, the cylinder template, and the
padded template as well as the padded template plus the constraint method. Overall, use of the
padded template resulted in smaller errors than the other two sets of templates. The padded
template was chosen for further study. The results were further improved when the padded
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template was combined with the constraint method. Figure 4 showed the scatter plots of the tumor
SI positions obtained from the markerless template matching method using the three methods of
templates, and also from the padded template combined with the constraint method. Ideally, the
plotted points should form a straight line; thus, the narrower the width of the distribution is, the
more the results agree with the marker estimation. The padded template has the least amount of
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outliers compared to the other two templates. And the padded template combined with the
constraint method further reduces the scatter. These results were consistent with the Table 1
results.

IV. DISCUSSION
Lewis et al. 33 developed a phase-binned based algorithm to reconstruct tumor trajectory from the
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2D estimation in CBCT projections for lung tumor. This method is able to reconstruct more accurate
tumor trajectory from less accurate markerless tracking results. Our study was to improve the
accuracy of the markerless tracking instead of improvement by reconstruction. The cylinder
template which they used in the study did not work well in our patients, because tumors in our
patients were larger lesions infiltrating the chest wall, hilum, or mediastinum. For this kind of tumors,
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the bounding cylinder around the GTV plus the margin included more non-tumor-related tissues
(different motion pattern with tumor) compared to small well-defined tumors. The extra information
degraded the 2D image registration results. The tracking results using the padded template showed
better agreement with the reference trajectory from the marker as expected. The padded template
had no artificial gradient compared to Ex-GTV template while had better-defined the tumor content
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compared to cylinder template. Their results were compared against physician contours at the
projection images. Physician delineation on each projection is very time-consuming and may be very
inaccurate. We employed the marker based validation method from our previous development to
validate our algorithms other than the physician contours. The accuracy of the marker-based
validation method was studied and the method was independent of the physician delineation.
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Yang et al. 40 implemented digital subtraction technique in the markerless tumor tracking to remove
high contrast overlying structures in the projections. They found that digital subtraction was capable
to emphasis tumor visibility in projections so that easier to preform markerless tracking and also
easier for physician to delineate. In this study, we focused at improving the template matching
aspect of the markerless tracking by constraining the tracking region from training. By shrinking the
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search region to the most possible region, the template matching was able to avoid the false
matching outside the region and find the real best match with a higher possibility. The limitation of
the constraint method would be in the case when the tumor motion encounters sharp temporal
gradient events (e.g. coughing).
The template matching method worked better for small well-defined tumors. As shown in Table 1,
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the final results by using the shape template and the constraint method, patients with well-defined
solid tumors (Patient 1~3) demonstrated better agreement with the marker estimation. And patients
with large and/or diffuse tumors (Patient4, 5), larger errors in both the validation and the tracking
were observed. For large tumors, it was found in analysis of 4DCT scans of these patients41 that the
markers were sometimes implanted in clusters in one region of the tumor. Such anisotropic
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implantation is only a problem for those tumors that deform during breathing, causing the motion of

the markers to diverge from that of the whole tumor. To deal with these issues, multiple template
tracking and deformable registration will be tested in future studies.
In this study, the impact of tumor shape change over the course of treatment was not evaluated. As
treatment progresses over time, the tumor contours from the planning CT will be less accurate than
235

at the later fractions due to tumor shrinkage. Potential solutions include affine or deformable
template matching, which we plan to evaluate in the future.

V. CONCLUSION
Visually, the marker painting using Laplacian interpolation successfully removed the marker from the
images and preserved high gradient boundaries with some blurring. The existence of markers in the
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projection images has influence on the accuracy of the image registration. The Laplacian
interpolation method is effective at reducing the effect of markers on the image registration. Out of
the three template generation methods, the padded template provides best results and should be
used in further studies. With the implement of the constraint method, the results are further
improved.
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Figure 1. Workflow of the MLTM algorithm for CBCT projections.2
Figure 2. Phantom images. Image (a) lung phantom with the tumor insert; (b) to (f) projection images
of the 5 scans. Projections (b) and (c) were scanned at the same setup couch position; projections (d),
(e), and (f) were scanned at the same setup position which was shifted 1 cm anterior, inferior and
250

right from scans (b) and (c). Image (g) was the marker masks of projection (f).

2

Figure 3. (a) Intensity image of Ex-GTV Template; (b) Gradient image of (a); (c) Gradient image of
padded template by zero padding (b) at region outside the threshold; (d) Intensity image of cylinder
Template; (e) gradient image of (d).

2

Figure 4. Scatter plots of tumor trajectories obtained from the markerless algorithm versus tumor
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trajectory from the marker at SI direction in mm. (a) Ex-GTV template; (b) Cylinder template; (c)
Padded template; (d) Padded template + constraint method.

2

Figure 5. Visual results of marker removal of the clinical cases. The first column was the original
projections with the markers contours in green; the second column was the result of marker
removed and the third column showed the marker removal results with a Gaussian noise added. 2
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Figure 6. Visual results of marker removal and the comparison of profiles for the phantom case. The
first column showed the phantom images and the profiles of the red lines were shown in the second
column correspondingly. The first row was from the tumor phantom with the attached markers
(green contours); the second row showed the marker removal results of row 1 and they were
compared against the reference as shown in row 3.
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VI. FIGURES

Figure 1. Workflow of the MLTM algorithm for CBCT projections.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

Figure 2. Phantom images. Image (a) lung phantom with the tumor insert; (b) to (f) projection images of the 5 scans.
Projections (b) and (c) were scanned at the same setup couch position; projections (d), (e), and (f) were scanned at
the same setup position which was shifted 1 cm anterior, inferior and right from scans (b) and (c). Image (g) was the
marker masks of projection (f).
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(a)

(b)

(d)

(c)

(e)

Figure 3. (a) Intensity image of Ex-GTV Template; (b) Gradient image of (a); (c) Gradient image of
padded template by zero padding (b) at region outside the threshold; (d) Intensity image of cylinder
Template; (e) gradient image of (d).

(a)

(b)

(c)
(d)
Figure 4. Scatter plots of tumor trajectories obtained from the markerless algorithm versus
tumor trajectory from the marker at SI direction in mm. (a) Ex-GTV template; (b) Cylinder
template; (c) Padded template; (d) Padded template + constraint method.

.

Original

Marker Removed

Noise Added

Case 1
Case 2
Figure 5. Visual results of marker removal of the clinical cases. The first
column was the original projections with the markers contours in
green; the second column was the result of marker removed and the
third column showed the marker removal results with a Gaussian noise
added.
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Reference

290

Marker Removed
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295
Figure 6. Visual results of marker removal and the comparison of profiles for the phantom case. The first column
showed the phantom images and the profiles of the red lines were shown in the second column correspondingly.
The first row was from the tumor phantom with the attached markers (green contours); the second row showed
the marker removal results of row 1 and they were compared against the reference as shown in row 3.
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Method

EX-GTV Template

Cylinder Template

Padded Template

Padded Template +
Constraint
Patient MAE SD
90%
MAE SD
90%
MAE SD
90%
MAE
SD
90%
(mm) (mm) error
(mm) (mm) error
(mm) (mm) error
(mm) (mm) error
(mm)
(mm)
(mm)
(mm)
1
3.4
5.6
10.1
3.1
4.5
6.8
2
2.8
3.9
1.7
1.6
3.3
2
8.6
8.5
17.9
6.3
9.0
17.8
3.1
5.3
7.3
1.0
1.3
2.0
3
4.2
5.0
9
6.8
6.8
14.8
3.1
4.3
7.3
2.3
2.6
4.9
4
4.7
6.8
13.8
6.4
3.7
9.7
4.4
6.0
10.7
2.9
3.2
5.9
5
5.6
6.2
11.5
7.9
6.7
17.6
4.7
5.8
10.3
2.7
3.3
5.5
Mean
5.3
6.5
12.4
6.1
6.4
13.3
3.5
5.0
7.9
2.1
2.5
4.3
Table 1. The mean absolute error (MAE), standard deviation (SD), 90% error interval of using each template method
and using the constraint method with the selected template method.
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